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Introduction: There are several unique characteristics in the epidemiology of 
prostate cancer (PrCA) that make it an interesting and important cancer to study. The 
first is that while prostate cancer is the most common cancer that men develop, it is one 
of the least common cancers that men die from. This indolent nature of PrCA has led to 
the idiom among health scientists that “men are more likely to die with PrCA than due 
to PrCA”. Just like other cancers, several individual-level risk factors (e.g., family history 
of the disease, age, and race) are well established for both PrCA incidence and mortality.  
It is becoming more common for health scientists to utilize innovative modeling 
techniques to describe the current epidemiologic characteristics of PrCA given its unique 
etiological nature and established individual-level risk factors. One such avenue of 
research is to understand how geography impacts the epidemiology of PrCA. The vast 
majority of studies incorporating a geographical component will model an area-level 
characteristic(s) and nest PrCA subjects within a geographical area where that area is 
treated as a random component (either as a random intercept or random effect). Yet 
another, more recent, approach is to account for the spatial autocorrelation of the 
geographical area of interest. 
Modeling individual-level geographical components (e.g., distance each subject 
travels to a healthcare facility), area-level geographical components (area-level risk 
factors and geographical area as a random effect) and the spatial autocorrelation of the 
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geographical area of interest within a succinct modeling framework. It is this gap 
in knowledge in simultaneously accounting for multiple geographical levels and 
components in PrCA epidemiology that this research was undertaken.  
Methods: To evaluate how geographic context impacts the epidemiology of 
PrCA, this research was divided into three parts. The first investigated the incidence of 
PrCA, the second the mortality, and the third the mortality-to-incidence ratio (MIR). 
Electronic medical records from the United States (US) Veteran’s Health 
Administration (VHA) served as the data sources for all individual-level information and 
aggregate demographic information. The US 2010 Decennial Census and 2007-2011 5-
Year American Community Survey (ACS) were used for all area-level information. The 
Social Vulnerability Indexes (SoVI®) was obtained from the University of South Carolina 
Hazards and Vulnerability Institute. The 2004 Rural-Urban Commuting Area Codes 
(RUCA) were obtained from the University of Washington. The geographical area of 
interest were all ZIP code tabulated area linked (ZCTA) ZIP codes in the state of South 
Carolina (SC) during the timeframe January 1, 1999 to December 31, 2015.  
Results: It was found that PrCA incidence among SC veterans who receive care at 
VHA facilities from 1999 – 2015 were at 35% and 39% increased risk if they reside in 
ZCTA-linked ZIP codes with SoVI® scores that were medium and high, respectively, as 
compared to those veterans residing in ZIP codes with low SoVI® scores. Also, the best-
fitting model for PrCA incidence accounted for the random effect of SC ZCTA-linked ZIP 
codes and accounted for the spatial autocorrelation between SC ZCTA-linked ZIP codes.  
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It was found that PrCA mortality among SC veterans who received are at VHA 
facilities from 1999 – 2015 were at 25% increased risk of death if they traveled more 
than 55 miles to receive care. Also, the best-fitting model for PrCA mortality accounted 
for the random effect of SC ZCTA-linked ZIP codes. 
It was found that the PrCA mortality-to-incidence ratio (MIR) was 0.17 for SC 
veterans who receive are at VHA facilities from 1999 – 2015. Stratified MIRs for 
standard risk factors for PrCA were found to vary by racial category, age at first VA visit, 
ZCTA-linked ZIP code level social vulnerability and ZIP code rurality. Collectively, it was 
found that MIRs by ZCTA-linked ZIP codes did not vary significantly in SC; however, two 
distinct clusters of ZCTA-linked ZIP code MIRs was found. 
Discussion: This research found that the epidemiology of PrCA among veterans 
who received care at VHA facilities from 1999 – 2015 varies by geographic location and 
context. This research has successfully used three distinct measures to characterize 
where a veteran resides: 1) linear distance to his most frequented VHA facility, 2) 
neighborhood characteristics of the ZIP code he resides in, and 3) the spatial 
autocorrelation of the ZIP code he resides in. 
The successful demonstration of the approach undertaken in this research has 
the potential to be replicated and expanded to use different geographical boundaries 
(e.g. counties), incorporate temporal factors, and evaluate other cancers and chronic 
diseases. This research approach has the potential to 1) allow health scientists to target 
areas of higher than- and lower than expected risk for PrCA, 2) allow clinicians to know if 
where a patient resides increases the risk for PrCA, and 3) provides further and detailed   
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evidence to policy makers to understand that where a veteran resides can influence 
his/her health. 
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CHAPTER 1  
INTRODUCTION AND SPECIFIC AIMS 
1.1 Introduction 
Cancer is the second leading cause of death in the United States of America 
(USA) accounting for approximately 22% of all deaths.1 While prostate cancer (PrCA) is 
the most common epithelial cancer, accounting for 19% of all new cancer cases in men, 
only 9% of cancer deaths in men are due to PrCA.2 This represents the smallest overall 
mortality to incidence ratio for all cancers for both men and women in the USA as a 
whole.2 
Between 2011 and 2015 the incidence of PrCA in the US was 109.0 per 100,000 
men while the mortality of PrCA during the same timeframe was 19.5 per 100,000 men.3 
However, both the incidence and mortality of PrCA in the US vary spatially.3 This can 
clearly be seen upon an examination of mapping either the incidence or mortality of 
PrCA within the US by state.; the incidence of PrCA varied by state from a high of 137.5 
per 100,000 (Louisiana) to a low of 78.6 per 100,000 (Arizona), and the mortality of PrCA 
varied from a high of 25.2 per 100,000 (Mississippi) to a low of 13.7 per 100,000 
(Hawaii).3 Furthermore, known risk factors for both the incidence and mortality of PrCA 
such as race, income, education, and other socio-demographic factors also exhibit 
spatial variation upon closer examination.4,5 To better understand how spatial variation 
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impacts PrCA incidence, mortality, and PrCA risk factors; a large sample size 
encompassing a wide geographical area is necessary. 
The United States Veterans Health Administration (VHA) meets the sample size 
requirements and has nationwide representation. The VHA is one of the largest 
healthcare providers in the USA. A key feature for the VHA is that it is not a fee-for-
service healthcare provider. Due to this, individuals’ financial status is not considered in 
providing treatment at the VHA. This makes the healthcare delivered by the VHA unique 
when compared to other healthcare providers in the USA. 
Attempting to eliminate or at least minimize the impact of an individual’s 
financial status is critical in the quality of care that one receives. The financial status of 
individuals is an important component to consider and account for when investigating 
any cancer in general. In regard to PrCA, the overall incidence of PrCA is higher in men 
who are at higher socioeconomic status (SES) levels as compared to men who are at 
lower SES levels.6-10 However, the incidence of advanced PrCA and higher mortality rates 
are more likely to occur in lower SES levels.6-9,11 This indicates that men who are more 
affluent have better healthcare access, therefore more likely to be diagnosed with PrCA 
earlier resulting in higher survivorship as compared to less affluent men. This issue is 
further complicated when race is accounted for because Black men are also more likely 
to have higher PrCA mortality rates as compared to White men.6,8,11 
While means-based provision of care is a commendable goal, disparities still may 
arise through a variety of insidious risk factors that create differences in exposure to as 
yet unidentified risk factors, early detection and receipt of treatment. These encompass   
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putative factors ranging from subtle differences related to racism and social class to 
biological differences that have not been fully elucidated yet. The current state of the 
science indicates that there may be some biological basis for racial differences observed 
for a variety of diseases, including PrCA and related comorbidities.12 
There also may be a racial difference due to societal norms that even VHA 
healthcare cannot account or compensate for. For example, how does proximity to a 
VHA facility influence disease incidence and mortality because those traveling over a 
certain distance receive mileage reimbursements? The VHA cannot dictate where their 
patients live; however, does where a VHA patient live influence disease incidence and 
mortality? 
1.2 Specific Aims 
The aims of this dissertation are to characterize whether geographical risk 
factors affect the epidemiology for PrCA among VHA patients in SC while controlling for 
known PrCA risk factors. The aims are: 
Aim 1: Examine the role of potential geographical risk factors at the individual 
and neighborhood levels while controlling for known risk factors in predicting 
incidence of PrCA among US veterans residing in SC. 
The first aim seeks to determine how best to predict incident PrCA within the SC 
VHA population based on individual-level risk factors, ZIP code characteristics that a 
VHA patient lives (neighborhood level), and geographical considerations (distance 
traveled to the treating VHA facility and spatial autocorrelation).  
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Aim 2: Examine the role of potential geographical risk factors at the individual 
and neighborhood levels while controlling for known risk factors in predicting 
mortality of PrCA among US veterans residing in SC. 
The second aim seeks to determine how best to predict PrCA mortality within 
the SC VHA population based on individual-level risk factors, ZIP code characteristics 
that a VHA patient lives (neighborhood level), and geographical considerations (distance 
traveled to the treating VHA facility and spatial autocorrelation). 
Aim 3: Determine whether risk factors for PrCA age-adjusted mortality-to-
incidence ratios among US veterans seeking VHA care vary spatially. 
The third aim will use the age-adjusted mortality-to-incidence ratios (MIR) of 
PrCA within each SC ZIP code. The MIR is a measure that standardizes mortality 
differences to incidence differences between populations. This third aim will seek to 
determine the spatial variation in PrCA risk factors influencing PrCA age-adjusted MIRs 




BACKGROUND AND MATERIALS 
2.1 Prostate Organ 
The prostate is an organ that is physiologically part of the male reproductive 
system. It is an exocrine gland that is approximately the size of a chestnut.13 It is 
situated directly below the bladder, surrounding the urethra between the bladder and 
the penis.13 The function of the prostate is to contribute the enzyme fibrolysin, citric 
acid, acid phosphatase, and several key minerals.13 This contribution accounts for 15 – 
30% of the seminal fluid by volume.13 
2.2 Prostate Cancer 
Prostate cancer (PrCA) is the leading type of cancer, accounting for 19% of all 
new cancer cases in men; however, it is a relatively indolent disease reflected in the fact 
that  only 9% of cancer deaths in men is due to PrCA.2 This is the smallest overall 
mortality to incidence ratio for any cancer, in both men and women.2 Adenocarcinomas, 
which arise from exocrine or endocrine glands, account for 99% of all PrCA cases.14 
Depending on the assessment of the virulence (i.e., metastatic potential) of an 
individual PrCA, it may not be necessary to treat the PrCA but instead to monitor its 
development.  In many PrCA patients, the cancer progresses extremely slowly.  Because 
of this, most (> 80%) men with diagnosed PrCA will die due to other causes rather than 
due to PrCA.2,15,16 Because of these considerations, it is evident why the American 
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Urological Association (AUA) is specific in its recommendations for PrCA screening for 
the general population.  However, the US Preventive Services Task Force views this 
same evidence and recommends against PrCA screening for the general population.16 
Both organizations, though, recommend men discuss their personal, individual risk 
factors for PrCA with their physicians as to guide subsequent decisions with regard to 
their individual PrCA susceptibility and decisions regarding screening conditional on this 
assessment. 
2.2.1 Screening 
As with all cancers, the anatomic and pathophysiological progression of PrCA 
dictates survival and treatment options. In general, the thinking is that the earlier the 
disease is detected and treated, the greater the probability of survival. Therefore, a key 
aspect of PrCA research is correctly identifying and characterizing the pathological phase 
of the PrCA – with the imperative that the screening test distinguishes virulent PrCA 
from any other prostate-related condition (including benign prostatic hypertrophy [BPH] 
and indolent cancer). However, a clinician must suspect the possibility of PrCA first, and 
then conjecture about disease virulence. One source of information is obtained via a 
digital rectal exam (DRE), which involves palpating the prostate. The purpose of the DRE 
is to identify an enlarged prostate, a “firm/hard” prostate, or abnormal prostate which 
could be indications of PrCA. However, simple enlargement of the prostate is relatively 
useless for distinguishing PrCA from other conditions such as BPH. Another source of 
information is the prostate specific antigen (PSA) level. The AUA notes that DRE as a   
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primary screening procedure lacks scientific evidence but is a useful test given increased 
PSA levels.16 
PSA, a protein specifically secreted by the prostate, is present in the blood, and 
can be quantified through assays using blood samples. In general, as men get older, 
their normal PSA baseline increases.17 However, an abnormally high PSA level, which 
varies depending on age, is an indication for further testing for possible PrCA.17 The use 
of PSA tests as a screening tool for PrCA in the early first half of the 1990’s is the reason 
why there was a spike in PrCA incidence rates (Figure 2.1). 
The (AUA) recommends that men who are not at increased risk should have PSA 
tests between 55 and 69 years old every two to four years.16 For those who are at 
increased risk for PrCA, the AUA recommends discussion with a physician.16 The AUA 
notes that the scientific evidence indicates that screening 1,000 men will result in one 
fewer death due to PrCA over the course of a decade.16 However, there are issues with 
using PSA tests to screen for PrCA.  In the United States it was found that PrCA based on 
PSA tests were over diagnosed by 42%.18,19 These studies are frequently cited as key 
scientific evidence that determine recommended guidelines for PSA testing. The 
disadvantages of PSA testing include a 75.9% false positive rate; which leads to a 12% 
chance of having at least one false positive (> 4.0 ng/ml) following three PSA tests every 
four years20, a 13% chance of having at least one false positive (> 4.0 ng/ml) following 
four PSA tests per year, and a 5.5% chance of having a biopsy as a result of the false 
positive.21 In addition, complications due to PrCA treatment include erectile dysfunction, 
urinary incontinence, loss of bowl control; and complications generally associated with   
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any surgery (including death) as well as those specifically arising from removing the 
prostate gland or having a prostate biopsy.15,16 
Given these considerations, making the most informed decision in the proper 
management of PrCA becomes more difficult. In other words, the identification of any 
PrCA is relatively easy as compared to how to treat it, which is strongly related to 
determining virulence which, in turn, is more difficult. The salient question is: Is it a PrCA 
that will progress slowly, if at all, for the remainder of the man’s life; and therefore the 
need for medical and surgical intervention is minimal (or even not necessary)? Or, is it a 
PrCA that will progress rapidly if untreated resulting in the death of the man; and 
therefore the risks of medical and surgical intervention are smaller than the risk of dying 
from PrCA? 
Being able to differentiate a PrCA that the man will die with from a PrCA that the 
man will die from will vastly improve clinical decision making and lower the medical cost 
for treatment. Significant research already has been conducted and continues to be 
conducted to refine differentiating between a PrCA that will cause death from one that 
will not.12,22-26 
2.2.2 Prostate Cancer Classification 
As with any solid tumor, the classification of PrCA is detailed. However, because each 
case of PrCA (as with any cancer) is unique; collapsing of this classification system 
becomes necessary for epidemiological research. Two classifications systems are 
commonly used for PrCA epidemiological studies.  
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The first is based on the size of the primary tumor and how far the cancer has 
spread, and is known as TNM staging (which refers to the size of the Tumor, Nodal 
involvement, and Metastatic spread). If the cancer cells are located only in the organ 
where they originated then the cancer is termed local (or localized). If the cancer cells 
have spread to the nearby tissues around the organ where they originated (e.g., lymph 
Nodes) then the cancer is termed regional. If the cancer cells have spread to other 
organs then the cancer is termed distant (i.e., Metastasized).27 Over time, and without 
any intervention, a cancer typically progresses from local to regional to distant.  
Epidemiologic studies typically will use TNM stage as a categorical variable in 
multivariable models.  Generally, either localized staging is used (no nodal involvement 
or metastatic spread) as the reference group, which is then compared to regional and 
distant stages respectively; or localized and regional staging are combined into one 
group to be used as the reference group and compared to distant stages. 
The TNM system is clinically focused.  However, if the sample size is sufficiently 
large in an epidemiological study, it may be possible to incorporate additional substrata 
and components of the TNM classification levels. This may provide additional insights 
into understanding the risk factors based on as much available clinical information on 
the progression of the cancer as possible. 
The second classification system is based on the extent of cancer cell 
differentiation seen, referred to as grade, and evaluated via the Gleason score. The 
Gleason score is a composite score from the summation of the two most prominent 
differentiations seen among the cancer cells in the tissue. Each differentiation pattern is   
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graded on a scale of 1 to 5; were 1 is the lowest score and closely resembles normal 
tissue and 5 is the highest score. A score of 5 indicates virtually no differentiation, and 
therefore no resemblance to normal tissue. Because the Gleason score sums the 
dominant and secondary patterns, the range of possible scores is from 2 to 10. 
Epidemiological studies and multivariable modeling will use the Gleason score as a 
continuous variable or may categorize it. Typically, two or three levels are used when 
the Gleason score is categorized. If two levels are used, then the cutoff is either ≤ 6 or ≤ 
7. If three levels are used, then the cutoffs are ≤ 5, 6 – 7, and ≥ 8. 
Gleason scores tend to be positively correlated with stage. As PrCA progresses, 
both the Gleason score and stage progress. However, progression of the PrCA will first 
be observed in the Gleason score, because it has more distinct levels than the staging of 
a cancer and is a better indication of its “biological behavior.” In other words, as the 
PrCA increases its Gleason score value by one, it may still remain in the same stage. 
Therefore, the Gleason score is a more sensitive and specific measure of PrCA 
progression rather than the stage of the PrCA. Because PrCA typically progresses slowly, 
the Gleason score becomes a more useful indication for PrCA progression than the 
staging value. 
2.2.3 Treatment 
Treatment for PrCA involves active surveillance, surgery, chemotherapy, 
radiation therapy, or a combination of any of these.27 Surgery involves either radical 
prostatectomy (removal of the prostate), if the cancer is localized, or pelvic lymph node 
dissection (in addition to prostatectomy) if it is more developed (e.g. regional).27 Initial   
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treatment is based on the evident progression of the PrCA and further treatment is 
based on the response of the PrCA to previous treatments.27 Courses in radiation 
therapy and chemotherapy are diverse and vary given the development of the PrCA.27 
The National Comprehensive Cancer Network Guidelines lists 15 types of therapies 
based on initial development of the PrCA and how treatment of the PrCA progresses.27 
2.3 Prostate Cancer Epidemiology 
2.3.1 Overall 
Over the last two decades, the incidence and mortality of PrCA appears to have 
stabilized with a 91.1% Five Year Survival if diagnosed in 2015 (Figure 2.1).28 
Furthermore, it is clear from Figure 2.1 that two additional interrelated phenomena can 
be observed. The first is that while there was a spike in PrCA incidence in the first half of 
the 1990’s, the mortality actually began the decreasing trend that it continues to this 
day. By identifying PrCA earlier in its development and treating it, this results in 
decreasing the probability of mortality. The second observation is that as PrCA was 
beginning to be identified and treated earlier in its natural history, the 5-year survival 
increased from 84.4% in 1989 to 95.2% in 1993. These positive trends in PrCA is rightly 
credited to the advent, use, and promotion of PrCA screening by the healthcare 
community. However, these are overall trends and more work needs to be done to 
eliminate disparities in PrCA incidence and mortality rates (e.g. as seen across racial 
categories, rural/urban categories, SES status, etc.).  
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While PrCA screening and treatment has significantly improved the probability of 
surviving PrCA, the risk of developing PrCA still remains.  As of 2013, one in six men will 
develop PrCA, and the risk of developing PrCA increases with increasing age.2 
2.3.2 Spatial Variability 
The importance of accounting for spatial variation among diseases and the 
application of spatially oriented techniques has been increasing rapidly within the last 
decade.29-32 Recognizing the importance of location as it relates to a disease has always 
been a key cornerstone of epidemiological research. Being able to fully assess that 
importance and impact, however, is a relatively new development for the epidemiology 
community.33-37 PrCA is no exception.  As seen in Figure 2.2, the incidence rate of PrCA 
in the US varies by state.38 The state with highest incidence rate of PrCA between 2011 
and 2015 was Louisiana with a rate of 137.5 per 100,00.38 The state with lowest 
incidence rate of PrCA between 2011 and 2015 was Arizona, with a rate of 78.6 per 
100,000.38 
As seen to the Figure 2.3, the mortality rate of PrCA in the US also varies by 
state.38 The state with highest mortality rate of PrCA between 2011 and 2015 was 
Mississippi with a rate of 25.2 per 100,00.38 The state with lowest mortality rate of PrCA 
between 2011 and 2015 was Hawaii, with a rate of 13.7 per 100,000.38 
Figures 2.2 and 2.3 indicate that there are areas in the US were both the 
incidence rate and mortality rate of PrCA are both high (e.g. the Southeast and 
Northwestern States). There also are states where incidence is only moderate, but 
mortality is very high given incidence (e.g., South Carolina, where White men have   
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relatively low PrCA incidence, Black men have very high incidence and extremely high 
mortality). 
As indicated in the prior sentence the spatial disparity seen in PrCA incidence 
and mortality rates is confounded by racial/ethnic disparities as well. This can be seen in 
the variations in incidence rates of PrCA in the US by race and ethnicity across states.39 
Among White Americans from 2011 to 2015, the highest incidence rate was in New 
Jersey (124.2 per 100,000) and the lowest was in Arizona (74.9 per 100,000) with high 
concentrations in the Mid-Northern States and North-Mid Atlantic States.39 Among 
Blacks from 2011 to 2015, the highest incidence rate was in Delaware (212.3 per 
100,000) and the lowest was in Idaho (106.4 per 100,000) with high concentrations in 
the Southern States and the Eastern States.39 Among Hispanic Americans from 2011 to 
2015, the highest incidence rate was in New York (134.7 per 100,000) and the lowest 
was in Alaska (42.8 per 100,000) with high concentrations in the North-Mid Atlantic 
States.39 
The mortality rates of PrCA in the US also varies by race and ethnicity across 
states.39 Among White Americans from 2011 to 2015, the highest mortality rate was in 
Idaho (23.8 per 100,000) and the lowest was in Florida (15.6 per 100,000) with high 
concentrations in the Mid-Northern States and Western States.39 Among Black 
Americans from 2011 to 2015, the highest mortality rate was in Arkansas (61.9 per 
100,000) and the lowest was in Iowa (23.5 per 100,000) with high concentrations in the 
Southern States and Prairie States.39 Among Hispanic Americans from 2011 to 2015, the   
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highest mortality rate was in New Mexico (19.4 per 100,000) and the lowest was in 
North Carolina (8.5 per 100,000).39 
It needs to be noted that the incidence and mortality rates for Black Americans 
and Hispanic Americans are not displayed due to rate stability. This suppression is due 
to there being fewer than 16 cases in that state.39 To overcome this issue for this 
dissertation research; multiple continuous years (1999 – 2015) will be used focusing on 
one state (i.e. South Carolina) and including only White and Black racial categories. 
While it is clear that PrCA incidence and mortality varies across states, it is only 
in recent years have researchers examined how spatial variation influences the 
incidence and mortality of PrCA. All of these studies have been at the state level: 
Florida40-42, Georgia43,44, South Carolina45-47, Texas48, Virginia49, Maryland50, and 
Massachusetts and Commecticut51 (Table 2.1). 
Several of these studies did not account for the spatial variation in inferential 
models, but rather identified whether spatial variation was present.43-45,48,51 Of these, 
one noted areas of higher PrCA mortality-to-incidence ratios45, three used a Scan 
Statistic that identifies adjacent areas of similar PrCA incidence43,51 and similar PrCA 
mortality48, one used a Z-test to identify areas with higher PrCA mortality-to-incidence 
ratios44, and one used observed-to-expected ratios to identify areas with higher PrCA 
incidence51. Furthermore, these studies used different geopolitical boundaries for their 
respective analyses; two used census tracts43,51, two used heath district/regions44,45, and 
one used counties48.  
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Seven studies accounted for the spatial variation present in inferential models 
(Table 2.1).40-42,46,47,49,50 Of these, two studies used kriging to predict the incidence of 
prostate cancer.40,41 Kriging is a geographical technique used to predict an unknown 
value in a given area of interest given the known values of the areas around the area of 
interest.33-37 Both of these studies used Florida counties as the geopolitical boundary of 
interest.40,41 
Two of the seven used multilevel modeling but did not directly account for the 
spatial variation in the models they used.42,50 In the first of these two studies; individual-
level risk factors, county-level environmental factors, and census-level demographic 
factors were used in multilevel, multivariable logistic regression models of late-stage 
and poor-grade differentiation of PrCA in Florida.42 Data from the Florida Cancer 
Registry was used.42 Both the late-stage and poor-grade differentiation logistic 
regression models had similar results for the individual-level risk factors; increasing age, 
being Black American as compared to White American, being a current smoker as 
compared to a non-smoker, and being a former smoker as compared to a non-smoker 
were risk factors while being married was a protective factor.42 Differences in risk 
factors appeared at the census tract level between the late-stage and poor-grade 
differentiation models.42 Increasing census tract median income and increasing percent 
college educated were protective in the late-stage model while only increasing percent 
college educated was protective in the poor-grade differentiation model.42 The county-
level environmental factors; water quality, superfund site, and toxic release were not 
significant for both models.42 In addition; a Black American-White American ratio of age-  
 
16 
adjusted PrCA incidence and PrCA late-stage incidence was determined for each 
county.42 This racial ratio of PrCA incidences identified Florida counties that had higher 
ratios than the state average ratio.42 This indicated Florida counties where the incidence 
of PrCA and late-stage PrCA incidence were higher among Black Americans than the 
state average when compared to White Americans.42 The highest age-adjusted PrCA 
incidence ratio was seen in Union County where Black Americans were 4.14 times more 
likely to develop PrCA than White Americans.42 The highest age-adjusted late-stage PrCA 
incidence ratio was seen in Holmes County where Black Americans were 8.69 times 
more likely to be diagnosed with late-stage PrCA than White Americans.42 
In the second of the two multilevel studies, the incidence for late-stage and high-
grade PrCA diagnosis from 1992 to 1997 were modeled in Maryland.50 Using the 
Maryland Cancer Registry and the 1990 US Census, the investigators developed a social 
resource index using census tract, census block groups, and county level information 
(i.e., neighborhood factors).50 Four multivariable models were constructed.50 The first 
two evaluated the incidence of being diagnosed with late-stage PrCA with one solely 
modeling individual level risk factors, and the other modeling individual and 
neighborhood level factors.50 The second two evaluated the incidence of being 
diagnosed with high-grade PrCA, with one modeling only individual-level risk factors, 
and the other modeling individual and neighborhood-level factors.50 For all four models, 
no census tract information was significant.50 The majority of risk factor estimates were 
consistent across both late-stage and high-grade models and across individual-level and 
multilevel models.50 There were three noteworthy risk factors.50 The first is that an   
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increase in county level social resources is protective for late-stage PrCA.50 The second is 
an increase in county level social resources is a risk factor for high-grade PrCA.50 These 
associations may seem to contradict each other; however, the investigators note that 
factors associated with diagnosis of high-grade disease are influenced by the 
distribution of resources in the community that mitigate other known risk factors for 
PrCA (i.e., stress, environmental factors, diet, occupation, etc.) and not by the quantity 
of resources.50 The third noteworthy risk factor is that while increasing income (as 
measured by median income at the census block group) is protective against high-grade 
PrCA; increasing income among Black Americans (as measured by median income and 
race at the census block group) is a risk factor.50 
One of the seven multilevel studies used individual-level information to describe 
the study population but used only neighborhood factors in its multivariable models.49 
The investigators used the Virginia Cancer Registry from 1990 to 1999 and the 1990 US 
Census.49 They developed multivariable models by census tract and county, and 
stratified by race (Black American and White American).49 For the county-level models, 
increasing age was a risk factor for PrCA among both Black Americans and White 
Americans.49 Among Black Americans, the interaction between residing in a county were 
10 to 19% are below the poverty level and in a majority non-rural county is a risk factor 
for PrCA.49 The census tract models produced more statistically significant predictors for 
PrCA incidence.49 Increasing age was still a risk factor for PrCA among both Black 
Americans and White Americans.49 Residing in majority non-rural census tract was a risk 
factor for PrCA among both Blacks and Whites.49 Increasing median household income   
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was also a risk factor for PrCA among both Black Americans and White Americans, but 
the effect was more than double among Black Americans as compared to Whtie 
Americans.49 Residing in a majority non-rural census tract was significant for both Black 
Americans and White Americans as median income increases, but in opposite directions; 
it was a risk factor for Black Americans and protective for White Americans.49 Unique 
risk factors for PrCA among White Americans were decreasing census tract poverty 
levels, increased percent of greater than high school education, increased percent of 
female heads of households, and increased physician to population ratio while 
increasing percent of being poor in the census tract was protective.49 No statistically 
significant unique risk factors for PrCA among Black Americans were evident.49 It is 
important to note that the investigators discussed the differences among risk factors 
between the census tract multivariable model and the county-level multivariable model; 
as well as, how the results of these neighborhood-level models differ from individual 
level factors and the ongoing scientific discussion of using socio-economic status 
measures as predictors for PrCA (especially among Blacks).49 
The final two studies accounted for the spatial variation in PrCA incidence and 
mortality within multivariable models.46,47 Both studies used South Carolina Cancer 
Registry Data, county as the geopolitical boundary, and both studies were from the 
same team of investigators.46,47 In the first study, the investigators evaluated three 
model types: baseline (logistic regression), proportional odds, and adjacent-categories 
logit model.46 Within each model type, they evaluated whether the distribution was 
spatially correlated or uncorrelated.46 In addition, the investigators also evaluated the   
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three model types without accounting for the location of the cases (i.e., models without 
any spatial information).46 Two outcomes were considered: comparing risk factors for 
being diagnosed with a distant stage PrCA as compared to a local stage PrCA, and risk 
factors for being diagnosed with a regional stage PrCA as compared to a local stage 
PrCA.46 There were 21 models that were evaluated within a Bayesian framework.46 
Given this, the model with the lowest Deviance Information Criteria (DIC) was used to 
select the best fitting model.46 
The model comparing late-stage to early-stage PrCA was a logistic regression 
model yet spatially uncorrelated by county.46 However, the uncorrelated spatial 
variation component remained in the model as a random effect.46 The statistically 
significant risk factors for being diagnosed with distant stage PrCA as compared to early-
stage PrCA include older age, and being Black American as compared to White 
American; while ever being married decreased the risk of distant stage PrCA (with 
currently married more protective than separated, divorced, or widowed).46 The model 
comparing regional to local PrCA was a logistic regression model with spatially 
correlated counties.46 Increasing age is a statistically significant protective factor for 
regional stage as compared to local stage PrCA.46 Being Black-American and any ever 
married category was not statistically significant factors.46 For both models, the year of 
diagnosis was statistically significant when compared to the earliest year, 1997.46 
Furthermore, with each successive year, the protective effect increases.46 In addition, 
the investigators tested the robustness of these models by altering the prior 
distribution, which had inconsequential impacts of the results and conclusions.46 Finally,   
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and most notably, because the investigators’ model comparing regional-stage PrCA to 
local-stage PrCA accounted for spatial variation, they were able to identify counties with 
higher (and lower) than expected incidences of regional stage PrCA.46 
The second study from this team of investigators incorporated the spatial 
variation in South Carolina PrCA patients between counties obtained again for the South 
Carolina Cancer Registry.47 In a unique and innovative modeling paradigm for cancer 
research, the investigators were able to model the risk factors for time to death (i.e. a 
survival analysis) while conditioning on the risk factors for the incidence of PrCA.47 In 
other words, given the risk factors for PrCA incidence, the risk factors for PrCA mortality 
were determined.47 As in their earlier study (already summarized), the authors used a 
Bayesian perspective with multiple model combinations to determine were spatial 
variation in PrCA is best accounted for.47 As before, the model with the lowest DIC was 
selected, which was a model were PrCA incidence was spatially uncorrelated yet 
remained in the model as a random effect estimate, but PrCA mortality was spatially 
correlated.47 Risk factors for PrCA incidence were being Black American as compared to 
White American, and being more likely to be diagnosed with regional stage PrCA than 
with local stage PrCA.47 Protective factors for PrCA incidence were being married, 
separated, divorced, or widowed as compared to single; and being diagnosed with 
distant stage or unstaged PrCA.47 In regard to PrCA staging, the investigators found that 
if someone is diagnosed with PrCA, the PrCA will most likely be in the regional stage.47 
Given the risk factors associated with PrCA incidence, the risk factors associated 
with PrCA mortality were being Black American as compared to White American; being   
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diagnosed with a regional, distant, or unstaged PrCA as compared to a local-stage PrCA 
(where distant stage had an almost 6.5 times increased risk); and increasing age.47 The 
only protective factor was being married as compared to single.47 Furthermore, this 
joint model fitted the data exceptionally well for men between 56 and 80 years old.47 
By being able to account for the factors associated with PrCA incidence, the 
random distribution of PrCA incidence by counties, the factors associated with PrCA 
mortality, and the spatial correlation of PrCA mortality; the investigators identified 
counties with higher than expected and lower than expected risk of PrCA mortality.47 
It is clear, based on this research that accounting for the spatial component of 
PrCA is not only important but necessary in identifying areas of high risk. It is also clear 
that if the spatial component cannot be incorporated into the models for any reason 
than nesting the risk factors based on geopolitical boundaries is the next logical 
approach. In other words, beginning and ending on the individual may not provide an 
accurate assessment of PrCA risk. 
2.4 Data Sources 
The first data source for this dissertation will be the United States Veteran’s 
Affairs Central Cancer Registry (VACCR). The VACCR is a national cancer registry that 
collects information on all cancer diagnoses among veterans seeking care in VA facilities. 
Information collected are divided into five broad categories; patient identification and 
demographics, cancer identification and diagnostic information, staging and extent of 
disease at diagnosis, first course of treatment, and outcomes.  
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The second data source will be the VA MedSAS® data files, which are files 
developed from electronic medical records for the purposes of analytical inquiries.52 
These files are divided into inpatient and outpatient files groups with data available 
beginning in 1999.52 The outpatient files are further divided into two file types; one file 
type documents an outpatient event and while the other file type documents an 
outpatient visit.52 The inpatient files are further divided into two groupings.52 The first 
describes the type of care received while the second describes the type of file (i.e., 
information) present.52 The type of care group is divided into acute care, extended care, 
observational care, and non-VHA care; while the type of file group is divided in the main 
file, bed section file (i.e. a medical record describing the care received at a specific 
inpatient room), procedure file, and surgery file.52 These two inpatient subgroups 
collective describe the 15 inpatient MedSAS® files in the VHA.52 
Information such as scrambled Social Security Numbers, ICD-9 Diagnosis and 
Procedure codes, race, date of birth, date of death, number of visits, type of visit, 
clinical service (e.g. oncology, cardiology, etc.), length of medical stay, ZIP code, county, 
etc. will be used to create a comprehensive cohort file of all VHA patients receiving care 
between 1999 and 2015. 
The third data source that will be used in this dissertation are the electronic VA 
Vital Status files.53 These two file types will provide detailed demographic information 
(e.g. date of birth, date of death, race, and ethnicity).53 
The fourth and fifth data sources will be the 2010 United States Census and the 
2007  2011 American Community Survey.54,55 Data from these sources will be used for   
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SC ZIP code level characteristics, and to determine a Social Vulnerability Index (SoVI®) 
for the continental United States based on ZIP code level information56-58. 
2.5 Software Programs 
The three key software programs that will be used for this dissertation will be 
Microsoft SQL Server®, SAS®, R®, and WinBUGS®.59-61 Microsoft SQL Server® will serve as 
the initial program in data management. SAS® will serve as the program for secondary 
data management, and primarily for data cleaning and data analysis for all three Aims.59 
R® will serve as the primary program involving the creation of maps depicting spatial 
information for all three Aims.61 The R® program for the VA will provide the geospatial 
information for counties, ZIP codes, ZCTA’s, and location of VHA facilities in the 
continental US61 In addition, R® will serve in the analysis for AIM 3.61 R® will serve as 
required in data analysis. In the possibility that AIMS 1 and 2 will be analyzed in a 
Bayesian framework, then WinBUGS® integrated through R® will serve as the primary 
data analysis programs.60,61 
In addition to the aforementioned central programs, this dissertation will also 
use a remote interface program to the VA servers known as VA Informatics and 
Computing Infrastructure (VINCI) for all data management, cleaning, and analyses 
involving VHA data. VINCI was developed by the VA as a resource to VA researchers. The 
three major advantages of VINCI are security, the wide variety of programs available, 
and computing power. All VHA data will reside within the VA servers which are behind 
the VA firewalls and meet the highest standards of data security for patient-level 
information. No researcher with access to VHA data can remove VHA data from within   
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the VA servers. VINCI therefore allows access to the data for research purposes but only 
summary information can be removed (i.e., model estimates, graphs, etc.). 
Furthermore, VINCI provides access to all the programs that are required for the proper 
completion of this dissertation. Lastly, the VA servers possess the computing power to 
effectively and efficiency store and analyze tens of millions of rows of information; as 
opposed to a personal high-end computer which will have the ability to analyze tens of 





Table 2.1. Summary of how peer-reviewed epidemiological publications accounted for spatial variation in prostate cancer 
research 
 
Type Article State Time Geographical Unit Data Source(s) Analytical Technique 
non-inferential SE Wagner, 
et. al. 44 
GA 2003 – 2007 Health Districts GA Cancer Registry Z-test to identify districts of higher than expected PrCA 
MIR’s*. 
non-inferential SE Wagner, 
et. al. 43 
GA 1998 – 2008 Census Tracts GA Cancer Registry Scan Statistic to identify clusters of census tracts with similar 
PrCA incidence. 
non-inferential JR Hébert, et. 
al. 45 
SC 2001 – 2005 Health Regions SC Cancer Registry Mapping SC health regions’ PrCA MIR’s with respective 95% 
Confidence Intervals. 
non-inferential CE Hsu, et. al. 
48 
TX 1980 – 2001 Counties Texas Vital Records, 1990 and 
2000 US Census 
Scan Statistic to identify clusters of counties with excess PrCA 
mortality. 
non-inferential LM DeChello, 
et. al. 51 
CT & MA 1994 – 1998 Census Tracts CT Tumor Registry, MA Cancer 
Registry, 1990 US Census 
Scan Statistic to identify clusters of observed-to-expected 
ratios among census tracts with higher PrCA incidence. 
inferential P Goovaerts 
and H Xiao 40 
FL 1981 – 2007 Counties FL Cancer Data Systems Kriging to extrapolate PrCA incidence based on jointpoint 
regression model. 
inferential P Goovaerts 
and H Xiao 41 
FL 1981 – 2007 Counties FL Cancer Data Systems Kriging to extrapolate late-stage PrCA incidence using 
longitudinal models. 
inferential H Xiao, et. al. 
42 
FL 1990 – 2001 Counties and Census 
Tracts 
FL Cancer Data Systems and 
2000 US Census 
Counties and Census Tracts as nesting variables for multilevel 
multivariable models predicting PrCA incidence. 
inferential H Zhou, et. al. 
46 
SC 1997 – 2001 Counties SC Central Cancer Registry Determine best fitting multivariable spatial model predicting 
PrCA incidence.  Spatial variation accounted for in models. 
inferential H Zhou, et. al. 
47 
SC 1997 – 2001 Counties SC Central Cancer Registry Determine best fitting multivariable spatial model predicting 
time to death while conditioning on the risk factors for the 
incidence of PrCA.  Spatial variation accounted for in models. 
inferential MN Oliver, et. 
al. 49 
VA 1990 – 1999 Counties and Census 
Tracts 
VA Cancer Registry and 1990 
US Census 
Counties and Census Tracts as nesting variables for multilevel 




et. al. 50 
MD 1992 – 1997 Counties and Census 
Block Groups 
MD Cancer Registry and 1990 
US Census 
Counties and Census Block Groups as nesting variables for 







Figure 2.1. Age-adjusted prostate cancer epidemiological trends in the United States 





















1Figure 2.1 was created using publicly available data from the National Cancer Institute 
(NCI) Surveillance, Epidemiology, and End Results Program Stat Fact Sheets: Prostate 







Figure 2.2. Overall prostate cancer incidence rate per 100,000 in the United States of 














2Figure 2.2 was created and export using the US Centers for Disease Control and 








Figure 2.3. Overall prostate cancer mortality rate per 100,000 in the United States of 














3Figure 2.3 was created and export using the US Centers for Disease Control and 






PATIENT AND AREA-LEVEL PREDICTORS OF PROSTATE CANCER AMONG SOUTH 
CAROLINA VETERANS: A SPATIAL ANALYSIS 
3.1 Abstract 
Background: Racial and socio-economic status (SES) disparities exist in prostate 
cancer (PrCA) incidence and mortality. Less is known regarding how geographical 
factors, including neighborhood social vulnerability, affect PrCA risk. The Veterans 
Administration Medical System provides a unique means for studying PrCA 
epidemiology among diverse individuals with ostensibly equal access to healthcare. 
Methods: From the US Veteran’s Health Administration electronic medical 
records database from January 1999 to December 2015, we identified 3,736 PrCA 
patients and 104,017 cancer-free controls from South Carolina (SC). Data were analyzed 
using a Bayesian multivariate conditional autoregressive model, which accounted for 
individual-level factors, area-level factors, spatial random effects and autocorrelation.  
Results: As expected, after accounting for age (6-fold and 13-fold increases in 
men 40-50 years and >50 years, respectively), race was an important risk factor, with 3-
fold higher odds among Blacks in the fully adjusted model [ORadj: 2.98 (2.77, 3.20)]. 
After accounting for all other factors, residing in a ZIP code with an intermediate level of 
Social Vulnerability Index (SoVI®) versus the lowest, least-vulnerable, ZIP codes, 
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increased PrCA risk by 35% [ORadj=1.35 (1.11, 1.65); while residing in the most socially 
vulnerable ZIP codes increased risk by 39% [ORadj=1.39 (1.11, 1.75).  
Conclusions: While accounting for known risk factors for prostate cancer, 
including age, race, and marital status, we found geographic areas in SC characterized by 
higher than average social vulnerability with higher rates of incident PrCA among 
veterans. Outreach for screening, education and care coordination may be needed for 
veterans in these areas. 
3.2 Introduction 
Prostate cancer (PrCA) is the most common cancer in men, accounting for 22% 
of all new cancer cases in American men.2 Identifying novel risk factors associated with 
PrCA risk beyond established risk factors has been met with little success. Well known 
risk factors include race, education, marital status, family history, diet, and age.2,7,14  
In the general United States (US) population, PrCA incidence displays a non-
uniform geographical distribution, where in 2015 the national average was 99.1 new 
PrCA cases per 100,000.62 The top three highest states being New Jersey (127.4.7 per 
100,000), Mississippi (126.7 per 100,000), and Louisiana (125.7 per 100,000) while the 
three lowest rates being Alaska (61.0 per 100,000), Nevada (69.5 per 100,000), and New 
Mexico (72.6 per 100,000).62 These differences across states may be potentially 
associated with macro-level factors such as area-level income, educational attainment, 
rurality, and environmental factors.42,49,50 Examining these potential area-level 
differences while accounting for individual-level risk factors for PrCA may provide   
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invaluable insight into better identifying individuals at higher than normal risk just by 
knowing where they live. 
Epidemiologic research is focused on evaluating putative disease risk factors, 
through the generation and testing of hypotheses related to risk factors across the 
socioecological spectrum including environmental exposures and social determinants of 
health. Identifying areas with higher- or lower-than-expected numbers of PrCA cases 
using spatial techniques43-45,48,51, employing spatial nested models42,49,50 or 
autoregressive models40,41, and using neighborhood factors of the geographical unit of 
investigation42,49,50 can provide a more thorough understanding of PrCA by expanding 
the list of risk factors associated with PrCA.40,41,46,47 In addition, accounting for spatial 
autocorrelation may allow researchers to improve on model fit, which in turn will allow 
them to determine geographical regions that are at increased or decreased risk for 
PrCA.37 
The goal of this study is to identify the impact of area-level characteristics 
including social vulnerability on incident PrCA diagnosis while controlling for established 
individual-level risk factors among veterans who receive care in the VA health care 
system, the largest universal access, integrated delivery system in the nation. We 
limited our analysis to veterans with PrCA cancer who were diagnosed and treated at a 
VA facility, who reside in South Carolina, a state with a higher incidence of PrCA cancer 
than the national average.38 A key consideration is that while the majority of men who 
receive care in the VA are of lower socioeconomic status, all have guaranteed access to 




3.3.1 Study Design 
This study employed a retrospective cohort design. The timeframe was from 01 
January 1999 to 31 December 2015. The unit of investigation was the US Census Bureau-
defined ZIP code tabulation areas (ZCTA), which consists of aggregated Zone 
Improvement Plan (ZIP) codes developed by the US Postal Service.63 All geographical 
related information was either linked to the shapefile (i.e. ZIP code patient level 
information linked to ZCTA’s in the shapefile), directly obtained at the ZCTA level (i.e. 
neighborhood-level information), or directly obtained from the 2015 ZCTA shapefile 
from the US Census Bureau (i.e. individual ZCTA boundaries).64 
3.3.2 Data Sources 
Data were obtained from the United States Department of Veteran Affairs and 
the United States Census Bureau. From the United States Department of Veteran Affairs 
the following datasets were used: all MedSAS® datasets, Master Vital Status dataset, 
Mini Vital Status dataset, and Primary Oncology dataset from the VA Cancer 
Registry.52,53 The VA Master Vital Status and VA Mini Vital Status datasets provided 
patient-level information (i.e., each unique VA patient is listed only once in these files) 
while the VA MedSAS® datasets provided visit-level information (i.e., with ≥1 
record/subject).52,53 From the United States Census Bureau the following datasets were 
used: United States 2010 Decennial Census, the 2007 – 2011 Five-Year American 
Community Survey, and the 2015 ZCTA shapefile for the US.4,5,64  
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3.3.3 Exclusion Criteria 
Subjects were excluded based on the following criteria (see Figure 3.1 for the 
STROBE Diagram establishing the analytic cohort)65: data in the Primary Oncology 
Dataset from the VA Cancer Registry could not be linked to MedSAS® datasets52, a non-
prostate cancer diagnosis in the Primary Oncology Dataset from the VA Cancer Registry, 
prostate cancer diagnosis in the Primary Oncology Dataset from the VA Cancer Registry 
prior to January 1, 1999, date of birth differs by more than 365 days between VA 
MedSAS® datasets52 and VA Vital Status datasets53, age during the timeframe did not 
wholly or partially fall between 40 and 70 years old, missing ZIP code information, racial 
classification other than white or black, and not residing in a South Carolina ZIP code. 
Overall, 964,047 unique subjects from a total of 1,159,188 (83.17%) unique 
cancer diagnoses were included in the Primary Oncology Dataset. Of these subjects, 
80.47% could be linked to unique patients in the MedSAS® datasets.52 
There were 235,782 unique PrCA cases in the Primary Oncology Dataset that 
could be linked to the VA MedSAS® Files. There were 230,401 (97.72%) PrCA cases were 
exclude due to not residing in a South Carolina ZIP code. Of the 5,384 PrCA cases 
residing in a South Carolina ZIP code; 1,648 (30.61%) were ineligible due to diagnosis 
prior to 01/01/1999, date of birth discrepancy, age at first VA visit not satisfied, missing 
ZIP code, and/or not being white or black. There were 9,976,241 unique subjects in the 
VA MedSAS® datasets that were not linked to any subjects in the VA Cancer Registry.52 
These subjects were classified as not having cancer. There were 9,798,934 (98.22%) 
non-cancer cases were excluded due to not residing in a South Carolina ZIP code. Of the   
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177,306 non-cancer cases residing in a South Carolina ZIP code; 73,289 (41.33%) were 
ineligible due to date of birth discrepancy, age at first VA visit not satisfied, missing ZIP 
code, and/or not being white or black. 
The final South Carolina analytical level cohort consisted of 3,736 subjects with 
PrCA and 104,017 non-cancer subjects (Figure 3.1). 
3.3.4 South Carolina Geographical Area 
South Carolina veterans receiving care at VHA facilities resided in 413 of South 
Carolina’s 424 ZIP codes (97.41%). The 2015 ZCTA shapefile from the US Census Bureau 
was used South Carolina ZCTA’s were in turn used to link the selected ZCTA’s to ZIP 
codes with identical designations in the VA MedSAS® Files.52,64 
3.3.5 Primary Outcome Variable 
Primary PrCA patients between January 1, 1999 and December 31, 2015 were 
identified from the VA Primary Oncology Dataset.52,53 Non-cancer controls were 
identified by removing all cancer patients in the VA Primary Oncology Dataset from the 
VA MedSAS® Files.52,53 Non-cancer controls were then limited to those patients whose 
first VA visit occurred between January 1, 1999 and December 31, 2015. 
3.3.6 Individual-Level Independent Variables 
The date of the first VA visit for each subject was obtained from the MedSAS® 
datasets and the date of birth (DOB) was obtained from the VA Mini Vital Status 
dataset.52,53 Four age strata variables were created: age <40, age from 40 – 50, age from 
>50 – 60, age from >60 – 70 years. The information located within the VA Master Vital 
Status file for race and ethnicity were classified into White, Black, Hispanic, Asian,   
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Hawaiian/Pacific Islander, and Native/Alaskan America, Other, and Unknown. Subjects 
other than white or black racial category were exclude because they accounted for 
9.90% of the PrCA and non-cancer patients.53 The marital status field at the time of 
diagnosis in the Primary Oncology Dataset was used for PrCA cases, while marital status 
field in the MedSAS® Outpatient dataset was used for controls to determine marital 
status for the cohort.52 Marital status was categorized as Married, Previously Married 
(Divorced, Widowed, Separated), and Never Married/Unknown. The unique VA facility 
numerical codes in the MedSAS® datasets were used to identify which facility a subject 
visited.52 The number of different VA facilities , the most frequented VA facility, and the 
number of times each subjected visited their most visited VA facility were determined. 
The ZIP code listed the most times for each subject’s total visits in the MedSAS® 
datasets was used for all ZIP code related information for each subject.52 For PrCA cases, 
the ZIP code at diagnosis was obtained from the Primary Oncology dataset. For PrCA 
cases, the ZIP code at diagnosis was used for cases without ZIP code information from 
the MedSAS® datasets (n = 6,784).52 
There were 131 unique VA facilities (i.e. VA hospitals and VA Community Based 
Outpatient Clinics) determined from VA MedSAS® datasets.52 The distance between the 
most frequented VA facility and ZCTA-linked ZIP code listed the most times was 
represented as a continuous variable and obtained using the MedSAS® datasets.52 This 
ZIP code information was linked to the 2015 ZCTA shapefile from the US Census 
Bureau.64 Using the shapefile, a contiguity straight line origin-to-destination matrix 
distance matrix between VA facilities and ZCTA code centroids to determine the   
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distance traveled by a veteran to his most frequented VA facility.52,64 The distance 
between the most frequented VA facility and the ZCTA-linked ZIP code listed the most 
times was categorized into: 0 – 25 miles, >25 – 55 miles, and >55 miles. These cutoffs 
were selected a priori to represent how many miles can approximately be driven within 
30 minutes, 1 hour, and more than 1 hour. 
3.3.7 Neighborhood-Level Independent Variables 
The Social Vulnerability Index (SoVI®): The SoVI®, initially developed by the 
Hazards and Vulnerability Research Institute (HVRI) at the University of South Carolina, 
is a composite measure of neighborhood-level factors obtained from publicly available 
population based datasets of factors associated with the health of individuals within 
those neighborhoods.58 The SoVI®  uses ZCTA measurements obtained from the 2010 US 
Census and the 2007 – 2011 5-Year American Community Survey.4,5 The SoVI® is a 
relative measure represented on a continuous scale from negative infinity to positive 
infinity in which the greater a geographical unit’s SoVI® score is the less prepared for, 
respond to, and recover from a disaster that area is compared to a geographical unit 
with a lower SoVI® score.66 A SoVI® score was assigned for each subject’s most 
frequently listed ZIP code. The SoVI® measurements were stratified into 3 categories 
using cutoffs of 1 standard deviations: Low (-∞, -2.04], Medium (-2.04, 2.79], and High 
(2.79, ∞). 
Specific Zip Code Level Factors: The 2007 – 2011 Five-Year American Community 
Survey was used to determine the percent of people within each ZCTA with at least a 
college degree with tertile cutoffs of [0%, 12.86%], [12.86%, 22.60%], [22.60%, 100%],   
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percent of people within each ZCTA living in poverty with tertile cutoffs of [0%, 7.96%], 
[7.96%, 15.86%], [15.86%, 100%], percent of Black Americans within each ZCTA with 
tertile cutoffs of: [0%, 0%], [0%, 2.73%], [2.73%, 100%], and percent of people within 
each ZCTA that were at least 65 years of age with tertile cutoffs of: [0%, 11.95%], 
[11.95%, 16.92%], [16.92%, 100%].5 
3.3.8 Statistical Analyses 
Descriptive statistics were calculated for the analytic cohort (i.e., t-test for all 
continuous independent variables and a chi-squared tests for all categorical  
independent variables). Frequentist multivariate models using SAS® were first 
developed to inform key steps in development and evaluation of the final models.59 
These models were developed for all individual level risk factors, and nested models 
incorporating both individual- and neighborhood-level risk factors with patient ZCTA-
linked ZIP code residence as a random effect were created for model selection 
purposes. Bayesian models were developed for the null (empty) models; individual-level 
models; nested models incorporating both individual, area-level risk factors, and 
accounted for patient ZCTA-linked ZIP code residence as a random effect; and the 
multivariate conditional autoregressive models incorporating both individual, area-level 
risk factors, accounted for patient ZCTA-linked ZIP code residence as a random effect, 
and accounted for the spatial autocorrelation between ZCTA-linked ZIP codes using 
queen contiguity based spatial weights (i.e. all bordering ZCTAs for a given ZCTA.will 
have a weight of 1 while all other ZCTAs will have a weight of 0).34,36,37  
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All categorical variables were evaluated using created dummy variables. Any 
independent individual-level variables where 95% confidence intervals could not be 
computed or extremely large point estimates with extremely wide 95% confidence 
intervals were excluded since those variables had almost all observations in one 
stratum. Independent individual-level variables not excluded were used in a manual 
backward stepwise approach to generate the final multivariate individual-level model 
were the added variable remained if it changed the risk factor estimates of the other 
variables by at least 10%. 
A manual backward stepwise approach was used to determine the final nested-
level model. Each neighborhood level independent risk factor was evaluated separately 
with the final multivariate individual-level model. The model with the lowest Akaike 
information criterion (AIC) was selected as the initial nested-level model.67 
Subsequently, the neighborhood factor with the next lowest AIC was added to the initial 
nested-model. If any risk factor estimates changed by more than 10% than the 
additional neighborhood factor remained. This was repeated for all neighborhood level 
factors. 
The median odds ratio (MOR) also was calculated for each model. The median 
odds ratio uses the area-level variance in the model and calculates a statistics that can 
be interpreted as the median difference in odds between the ZCTA-linked ZIP code with 
the highest compared to the lowest risk for two individuals with the same evaluated risk 
factors (i.e. the MOR is the risk estimate for the unexplained variation in the model).68   
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Therefore, the model with the best fit will also have the lowest MOR because risk 
factors in the model account for more of the variance in the outcome. 
A Global Moran I’s Test was conducted on the ZCTA-linked ZIP code level 
residuals of the final models to determine existence of spatial autocorrelation.37 If the 
Global Moran I’s Test was statistically significant, indicating the presence of spatial 
autocorrelation, then models accounting for spatial autocorrelation would be 
constructed using risk factors included in the final nested-level models. If the Global 
Moran I’s Test was statistically nonsignificant, indicating no presence of spatial 
autocorrelation in the data, then the nested-level model would become the final overall 
model for that comparison. 
Based on the frequentist models, the final Bayesian models were developed. A 
Bayesian framework was selected for all final models because we assumed the factors 
associated ZIP code residence are not independent and random between neighboring 
ZIP codes and therefore will have a structured variance that needs to be accounted for. 
Incorporating a conditional autoregressive (CAR) component into the models is the most 
popular way to account for this structured variance. The most appropriate framework 
when incorporating a CAR component in the models is to use a Bayesian framework. It 
was decided prior to modeling building that since models incorporating a CAR 
component would have to be conducted in a Bayesian framework then all other final 
models would also be conducted within a Bayesian framework so as to compare 
between final models.  
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All Bayesian models used uninformed priors. The initial statistical inference from 
each Bayesian model was based on 15,000 iterations (i.e. samples) after 5,000 burn-in 
period (Figure 3.2). The convergence of the sample chains was evaluated using the 
Geweke diagnostic, which compares the first 10% of kept iterations to the last 50% of 
kept iterations.69 The mean value was used as the point estimate for each individual and 
area level risk factors as well as the MOR estimates. The 2.5% and 97.5% iteration 
cutoffs were used as the ranges for the 95% credible intervals (CrI) for each risk factor. 
Bayesian models created were compared to each other using the Deviation 
Information Criteria (DIC).60 The model with the lowest DIC was selected as the best-
fitted model for that comparison in that analytic cohort. 
3.3.9 Logistical Aspects 
All data storage, management, and analyses were conducted with the VA 
Informatics and Computing Infrastructure (VINCI) servers. All data management was 
done using Microsoft SQL Server. All univariate and frequentist modeling analyses were 
conducted using SAS® version 9.4 software.59 All Bayesian modeling was conducted 
using WinBUGS® version 1.4.3 and R version 3.3.2.60,61 All evaluation of Bayesian 
modeling was conducted using R.61 All statistical tests used an α-level of 0.05. This 
project had Institutional Review Board Approval from the University of South Carolina 
(Pro00036431) and the William Jennings Bryan Dorn VA (10404). 
3.4 Results 
PrCA patients accounted for 3.5% of the final analytical cohort. The plurality of 
patients were between >60 to 70 years of age (37.7%). Most prostate cancer patients   
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were white (65.5%), married (62.3%), and travelled more than 55 miles to a VA facility 
for care (52.0%) (Table 3.1). The median distance traveled to a VA facility was 60.0 
miles. 
3.4.1 Univariate Statistics 
PrCA patients were more likely than non- PrCA patients to be older for their first 
VA visit (age from > 50 – 60 years: 45.1% vs. 34.0%; age from > 60 – 70 years: 41.0% vs. 
37.6%). PrCA patients were also more likely to be Black (54.5% vs. 33.6%), less likely to 
be have been married at diagnosis (58.4% vs. 62.5%), more likely to be have been 
previously married (32.7% vs. 22.4%), less likely to never have been married or have an 
unknown marital status (9.0% vs. 15.1%), and more likely to travel between 25 and 55 
miles to a VA facility to receive care than their non-cancer counterparts (Table 3.2). 
3.4.2 Multivariable Bayesian Modeling 
Seven models of increasing complexity using a Bayesian framework were fit 
(Table 3.3). All independent variables were significant for the first model. The second 
model was the nested null model where the subject’s ZCTA-linked ZIP code was 
accounted for. This model had a MOR of 1.37 (1.30, 1.44) as well as the highest DIC of all 
seven models. The third model accounted for the individual-level factors as well as 
nesting the subjects in their ZCTA-linked ZIP codes. The fourth model included area-level 
factors including percent of the population living in poverty and categorized SoVI® 
scores. While Model 3 and Model 4 have identical DICs, Model 4 had a smaller MOR 
indicating a better fitted model. The fifth model was the spatial null model with a spatial   
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random effect and autocorrelation term. Model 5 fit the data better than Model 2, with 
both a smaller DIC and MOR. The sixth model was the spatial model with only the  
individual-level factors. The seventh model was the spatial model with the individual-
level factors as well as the ZCTA poverty level and the categorized SoVI® scores for each 
model. The fifth model was the spatial null model with a spatial random effect and 
autocorrelation term. Model 5 fit the data better than Model 2, with both a smaller DIC 
and MOR. The sixth model was the spatial model with only the individual-level factors. 
The seventh model was the spatial model with the individual-level factors as well as the 
ZIP code poverty level and the categorized SoVI® scores for each model. 
Model 7, the most complex model, had the smallest DIC and MOR [1.14 (1.11, 
1.19)] of all the models, indicating that it is the model with the best fit. PrCA patients 
were more likely to be older when they had their first VA visit as compared to non-
cancer patients, with the risk increasing with increasing age; 40 – 50 years old (ORadj: 
5.63 (3.94, 8.39), >50 – 60 years old [ORadj: 13.11 (9.29, 19.53)], and >60 – 70 years old 
[ORadj: 13.31 (9.44, 19.81)]. PrCA patients were more likely to be Black [ORadj: 2.98 
(2.77, 3.20)]. PrCA patients were more likely to have been married previously as 
compared to being currently married [ORadj: 1.47 (1.37, 1.58)].  However, those who 
had never been married or their marital status was unknown were at lowest risk relative 
to those who were married [ORadj: 0.55 (0.49, 0.62)]. 
Distance between 25 and 55 miles from the patient’s ZCTA-linked ZIP code 
centroid to the most frequented VA facility was statistically insignificant in Model 7 
[ORadj: 1.06 (0.92, 1.21)]. This stratum for this variable was also statistically insignificant   
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in Model 4 while statistically significant for Models 1, 3, and 6. In model 7, PrCA patients 
were less likely to be living more than 55 miles from the patient’s ZCTA-linked ZIP code  
centroid to the most frequented VA facility vs. their non-cancer controls [ORadj: 0.86 
(0.75, 0.98)]. This stratum for this variable was also statistically significant in Model 4 
while statistically insignificant for Models 1, 3, and 6. 
PrCA patients were more likely to live in ZCTA-linked ZIP codes with a SoVI® class 
1 - 2 standard deviations from the ZCTA-linked ZIP codes with the lowest Social 
Vulnerability Index [ORadj: 1.35 (1.11, 1.65)] and 3 standard deviations from the ZCTA-
linked ZIP codes with the lowest SoVI® score [ORadj: 1.39 (1.11, 1.75)]. These estimates 
remained consistent and statistically significant for all models that accounted for them. 
Residing in ZCTAs with the highest poverty level (>= 15.86%) increased the risk of 
PrCA by 24% in Model 4 [ORadj: 1.24 (1.01, 1.48)]. However, this ZCTA poverty level was 
statistically insignificant after accounting for the spatial autocorrelation between ZCTAs 
in Model 7 [ORadj: 1.13 (0.93, 1.35)]. 
3.5 Discussion 
Our study identified an association between a veteran’s ZCTA-linked ZIP code of 
residence and prostate cancer risk. This study used a unique approach to account for 
individual-level risk factors, area-level risk factors, and spatial random effects and 
autocorrelation within one modeling framework. 
The distance traveled to receive care demonstrates a unique dynamic. When 
distance is the only measure describing the location of a veteran (i.e., Model 1), it is   
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statistically significant for those veterans traveling between 25 and ≤55 miles (i.e., a VA 
healthcare facility within an approximate 30-minute to 1-hour commute). That stratum  
remains statistically significant (i.e., Models 3 and 6), until accounting for ZCTA poverty 
level and SoVI® (i.e., Models 4 and 7). 
Interestingly, veterans traveling >55 miles (i.e. a VA healthcare facility more than 
an approximate 1-hour commute), became a statistically protective effect when ZCTA 
poverty level and SoVI® were accounted for (i.e., Models 4 and 7). This protective effect 
may be an indication of those veterans living in rural areas.8 The primary VA healthcare 
facilities in South Carolina are located in urban areas, which are limited to South 
Carolina. The rural/urban distinction of a ZIP code proceeds towards rural as the 
distance between VA facilities in South Carolina and a veteran increase. Obertova et. al. 
concluded in their systematic review article on the urban-rural disparity in PrCA that 
those living in rural communities could be less likely to seek preventive/wellness care 
visits, which in turn, are less likely to be screened for PrCA and thereby less likely to be 
diagnosed with prostate cancer resulting in a fewer PrCA cases being associated with 
that area.8 
A potential dynamic that will be explored in future research is what type of VA 
facility a veteran receives his care; is it a VA hospital or a VA Community Based 
Outpatient Clinics (CBOC). CBOC’s serve an important function in providing care to 
veterans living in less populated regions; however, CBOC’s are limited in what type of 
care they can provided. This analysis did not differentiate between VA hospitals and   
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CBOCs. However, based on the plausible conclusions inferred by these results, 
determining if differences exist between veterans who receive care at a VA hospital and  
a VA CBOC may be beneficial in improving how health care is delivered to this 
population. 
Our results demonstrated that more than one area-level risk factor was 
associated with higher rates of incident PrCA in the VA population. The models 
confirmed that area poverty was associated with higher incidence of PrCA.6,70 However, 
of key interest, is our finding that models accounting for the spatial autocorrelation 
between ZCTA-linked ZIP codes diminished the impact of area poverty while the SoVI® 
estimates remained similar. While a poverty level of >15.9% went from being 
statistically significant in Model 4 to statistically non-significant in Model 7, risk 
estimates for the SoVI® remained statistically significant and stable across those models. 
A credible explanation is that poverty levels for a community cannot be constrained by 
political/administrative boundaries such as ZIP codes, therefore when spatial 
autocorrelation is accounted for as in Model 7, it inherently accounts for similarities 
such as poverty level. However, the SoVI® is a composite measure that includes multiple 
community-level measures that cannot be fully accounted for by spatial autocorrelation 
alone. This opens the possibility of further exploration of how the measures that 
comprise the SoVI® individually and collectively impact the outcome of interest. 
While addressing societal issues of poverty and community social vulnerability is 
outside the scope of the VA, these results indicate that veterans living within an 
approximate 30-minute to 1-hour commute to a VA healthcare facility maybe at   
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increased risk for being diagnosed with an incident case of prostate cancer, especially if 
they reside in a ZIP code with a high percentage of the population in poverty and an  
increased SoVI® class. These results may indicate 1) a false sense of health assurance 
knowing that they live within 1-hour of VA facility, but do not choose to utilize the VA 
facility for preventive care/wellness/routine care; 2) a veteran who requires increased 
healthcare services chooses to live closer to a VA facility; or 3) an indication of the 
urban/rural dynamic within the veteran population seeking care at VHA facilities.8 
We also showed that established prostate cancer risk factors, such as marital 
status and being Black, were statistically significant factors associated with PrCA.2,71-73 In 
addition, their respective point estimates and 95% credible intervals were nearly 
identical for all models. 
Findings on age at first VA visit can provide insight into understanding age of 
prostate cancer diagnosis for veterans. Veterans diagnosed with incident prostate 
cancer were more likely to begin their VA healthcare later in life than those veterans 
without incident prostate cancer or who did not develop incident prostate cancer during 
the 16-year study timeframe. Furthermore, the risk of incident prostate cancer more 
than doubled from the 40 – 50 to the >50 – 60-year-old strata, at which point there was 
slight differences in incident prostate cancer risk between the >50 – 60 and >60 – 70-
year-old strata. This risk of age at first VA visit may also be caused by the recent influx of 
new veterans who served in Operations Enduring Freedom and Iraqi Freedom resulting 
in a larger population of younger veterans in the VA system who are still at risk for 
developing chronic diseases such as prostate cancer but may cause a bias when used as   
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part of a larger comparison group to evaluate those chronic diseases at this point in 
time.  
3.5.1 Strengths and Limitations 
This study used electronic medical records for patient-level variables. As such, 
issues that are inherent in using such information are present.74 The data files used have 
been extensively utilized and queried in other VA-based peer-reviewed research and are 
of high reliability and validity.75-78 Furthermore, biases that may be present between 
PrCA  patients and non-cancer patients will be non-directional because data 
management and cleaning did not differentiate between those patients. Of course, use 
of pre-existing datasets precludes examining data outside of its intended scope. For 
example, we had no information on putative prostate cancer risk factors including diet, 
physical activity, cardiorespiratory fitness, and a host of other psychosocial factors. 
The use of ZCTA’s as a proxy for ZIP codes as the geographical unit of analysis has 
been demonstrated to have boundary representation issues especially for non-
populated ZCTA’s as compared to ZIP codes.79 However, limiting the population under 
investigation to South Carolina, which is a small, stably-populated state as compared to 
the rest of the nation should mitigate the boundary issue. Therefore, the only areas 
impacted by boundary issues are those ZCTAs bordering the states of Georgia and North 
Carolina, which is always present in all spatial analyses where there is an adjacent area 
not included in the analysis. 
South Carolina veterans who were not excluded and yet received healthcare 
services at a VA facility not in South Carolina were still included in the analyses.   
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Receiving care at a South Carolina VA facility was not an exclusion criterion for that 
reason. The closet VA healthcare facility may be located across the state line for many  
border areas of the South Carolina. This occurrence does not impact the analyses in 
determining if residence-specific characteristics are associated with PrCA. 
More importantly, the ZCTA was selected as the geographical unit of analysis because it 
was the most appropriate choice to assess the spatial impact of prostate cancer 
epidemiology for two reasons. The first is that it was the smallest of the two 
geographical units available (the other being county). The second is a consequence of 
the first reason. The more homogenous the population was, the more likely to 
differentiate between ZCTA’s in the models and therefore identify ZCTA’s with higher 
and lower than expected risks for PrCA. As the geographical unit area increases, the 
population becomes more heterogenous in characteristics that could not be assessed. 
This increases the likelihood of introducing an unaccounted for directional bias. 
No South Carolina ZIP code maps were presented identifying crude counts, crude 
rates, or ZCTA specific risk estimates because ten of the 413 ZIP codes (2.4%) had, at 
most, five VA patients. Therefore, any presentation identifying location even at the 
aggregate level would violate the Health Insurance Portability and Accountability Act of 
1996.80 The research approach undertaken should not be discounted due to the 
limitation of what can be presented in the public domain. This research has the most 
benefit if used as an internal resource in identifying ZIP codes where the risk for a 
specific disease is above or below what is expected after controlling for known risk 
factors. In this regard, additional resources may be better directed toward   
 
49 
understanding what is driving a higher-than-expected disease risk in a specific area. This, 
in turn, could lead to targeting interventions by public health researchers that have the  
potential to benefit a specific community in need to better improve their health 
outcomes. Furthermore, clinicians can use this research in factoring in a patient’s 
residence as a potential risk factor for specific diseases. 
Finally, in addition to known risk factors for PrCA (race and marital status), we 
identified the unique factors such as area of residence and waiting to begin VA 
healthcare services until later in life as risk factors for incident PrCA. We demonstrated 
that location-specific characteristics as a risk factor for PrCA can be evaluated and 
accounted for at three levels; the individual level, community level, and the spatial 
autocorrelation among the ZIP codes. Expanding on the known risk factors for PrCA will 
allow clinicians to better assess a man’s likelihood for developing PrCA thereby 
improving the preventive care he receives.
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Table 3.1. Descriptive Statistics of South Carolina veteran population who seek 
healthcare at Veteran Health Administration facilities from January 1, 1999 to December 
31, 2015 and meet the study inclusion criteria 
 
Categorical Variables N = 107,753 (%) 
Prostate Cancer  
Yes 3,736 (3.47) 
No 104,017 (96.53) 
Age at First VA Visit (years)  
< 40 8,259 (7.66) 
40 – 50 21,848 (20.28) 
>50 – 60 37,052 (34.39) 
>60 – 70 40,594 (37.67) 
Race  
White 70,703 (65.62) 
Black 37,050 (34.38) 
Marital Status  
Married 67,173 (62.34) 
Previously Married 24,520 (22.76) 
Never Married/Unknown 16,060 (14.9) 
Preventive Care Visit  
Yes 104,644 (97.11) 
No 3,109 (2.89) 
Digital Rectal Exam  
Yes 104,023 (96.54) 
No 3,730 (3.46) 
Distance Traveled (Miles)  
0 – 25 31,200 (28.96) 
>25 – 55  20,515 (19.04) 





Table 3.2. Univariate χ2 analysis comparing all prostate cancer patients to non-prostate cancer patients for all categorical 
variables among the South Carolina veteran population who seek healthcare at Veteran Health Administration facilities from January 
1, 1999 to December 31, 2015 and meet the study inclusion criteria 
 
Risk Factors All PrCA Patients (n = 3,736) Non-Cancer Patients (n = 104,017) p-value 
Age of first VA visit (years)   <0.001 
< 40 31 (0.83%) 8,228 (7.91%)  
40 – 50 490 (13.12%) 21,358 (20.53%)  
>50 – 60 1,684 (45.07%) 35,368 (34.00%)  
>60 – 70 1,531 (40.98%) 39,063 (37.55%)  
Race*   <0.001 
White 1,662 (44.49%) 69,041 (66.37%)  
Black 2,074 (55.51%) 34,976 (33.63%)  
Marital Status   <0.001 
Married 2,181 (58.38%) 64,992 (62.48%)  
Previously Married 1,222 (32.71%) 23,298 (22.40%)  
Never Married/Unknown  333 (8.98%) 15,727 (15.12%)  
Distance Traveled (Miles)   <0.001 
0 – 25 1,071 (28.67%) 30,129 (28.97%)  
>25 – 55 910 (24.36%) 19,605 (18.85%)  





Table 3.3. Odds ratios and 95% credible intervals for multivariate models comparing prostate cancer patients to non-cancer 
patients among the South Carolina veteran population who seek healthcare at Veteran Health Administration facilities from January 
1, 1999 to December 31, 2015 and meet the study inclusion criteria 
 
Risk Factors Model 1* Model 2* Model 3* Model 4* Model 5* Model 6** Model 7*** 
Age of first VA visit 
(years) 
       
< 40  Reference N/A Reference Reference N/A Reference Reference 
40 – 50 5.60 (3.88, 8.36) N/A 5.72 (4.06, 8.13) 5.62 (4.03, 7.61) N/A 5.55 (3.94, 7.91) 5.63 (3.94, 8.39) 
>50 – 60 13.38 (9.40, 19.93) N/A 13.48 (9.67, 19.03) 13.14 (9.51, 17.67) N/A 13.03 (9.33, 18.62) 13.11 (9.29, 19.53) 
>60 – 70 13.60 (9.51, 20.25) N/A 13.67 (9.79, 19.30) 13.36 (9.64, 17.90) N/A 13.23 (9.45, 18.82) 13.31 (9.44, 19.81) 
Black 3.07 (2.87, 3.29) N/A 3.02 (2.81, 3.24) 2.96 (2.75, 3.18) N/A 3.03 (2.82, 3.25) 2.98 (2.77, 3.20) 
Marital Status        
Married Reference N/A Reference Reference N/A Reference Reference 
Ever Married 1.50 (1.40, 1.61) N/A 1.49 (1.38, 1.60) 1.47 (1.37, 1.58) N/A 1.48 (1.38, 1.59) 1.47 (1.37, 1.58) 
Never Married 
/Unknown 
0.57 (0.50, 0.64) N/A 0.56 (0.49, 0.63) 0.55 (0.49, 0.62) N/A 0.56 (0.50, 0.63) 0.55 (0.49, 0.62) 
Distance traveled from 
the most listed ZIP 
code (Miles) 
       
0 – 25 Reference N/A Reference Reference N/A Reference Reference 
>25 – 55  1.21 (1.10, 1.32) N/A 1.20 (1.07, 1.34) 1.08 (0.96, 1.22) N/A 1.16 (1.01, 1.33) 1.06 (0.92, 1.21) 
>55 0.96 (0.89, 1.04) N/A 0.95 (0.86, 1.04) 0.88 (0.80, 0.98) N/A 0.92 (0.80, 1.06) 0.86 (0.75, 0.98) 
Percent of population 
in ZIP code living in 
poverty 
       
0 – 7.96 N/A N/A N/A Reference N/A N/A Reference 
>7.96 – 15.86 N/A N/A N/A 1.04 (0.87, 1.24) N/A N/A 0.94 (0.78, 1.14) 
>15.86 N/A N/A N/A 1.24 (1.04, 1.48) N/A N/A 1.13 (0.93, 1.35) 
SoVI®        
Low N/A N/A N/A Reference N/A N/A Reference 
Medium N/A N/A N/A 1.27 (1.05, 1.56) N/A N/A 1.35 (1.11, 1.65) 
High N/A N/A N/A 1.27 (1.01, 1.58) N/A N/A 1.39 (1.11, 1.75) 
Median Odds Ratio N/A 1.37 (1.30, 1.44) 1.20 (1.15, 1.26) 1.17 (1.12, 1.22) 1.23 (1.16, 1.31) 1.17 (1.12, 1.22) 1.14 (1.11, 1.19) 
DIC 30,539 32,079 30,430 30,430 32,067 30,411 30,408 
Model 1: Individual Level Risk Factors; Model 2: Nested Null Model; Model 3: Nested Model with Individual Level Risk Factors; Model 4: Full Nested Model; Model 5: Spatial Null Model; Model 6: 
Spatial Model with Individual Level Risk Factors; Model 7: Full Spatial Model 
N/A: not applicable; *All 15,000 iterations after a burn-in of 5,000 iterations were evaluated; **Every fifth iteration of 25,000 iterations after a burn-in of 15,000 iterations were evaluated; ***All 


































Figure 3.1. STROBE Diagram for the generation of the analytical cohort comparing prostate cancer patients to non-cancer 
patients among the South Carolina veteran population who seek healthcare at Veteran Health Administration facilities from January 
1, 1999 to December 31, 2015 and meet the study inclusion criteria 
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Figure 3.2. Systematic plan for Bayesian model evaluation of the analytical cohort 
comparing prostate cancer patients to non-cancer patients among the South Carolina 
veteran population who seek healthcare at Veteran Health Administration facilities from 
January 1, 1999 to December 31, 2015 and meet the study inclusion criteria 
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NEIGHBORHOOD INFLUENCES ON PROSTATE CANCER MORTALITY AMONG SOUTH 
CAROLINA VETERANS 
4.1 Abstract 
Background: Established risk factors for prostate cancer (PrCA) mortality include 
age at diagnosis, TNM tumor stage, and Gleason score, family history and race. Only 
recently have factors related to PrCA patients’ residence on PrCA mortality begun to 
receive serious attention. We used electronic medical records from the Veterans Health 
Administration (VHA) to assess geographical factors and established risk factors for PrCA 
mortality. 
Methods: US VHA electronic medical records from January 1999 to December 
2015, were used to identify 3,073 PrCA patients residing in 346 ZIP codes within South 
Carolina (SC). Data were analyzed using a Bayesian multivariate conditional 
autoregressive modeling framework with mortality as the outcome, while accounting 
for individual-level factors, area-level factors (i.e. ZIP code tabulation area-level), spatial 
random effects and spatial autocorrelation. 
Results: Residing >55 miles from the VHA facility was associated with a 25% 
elevated risk of dying, [ORadj: 1.25 (1.04, 1.50)], after accounting for age at diagnosis 
(1.65-fold and 2.34-fold increases in men >60 – 70 years and those >70 years, 
respectively). Gleason score of ≥7 and TNM distant stage were important risk factors in 
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the fully adjusted model [ORadj: 1.51 (1.26, 1.82)] and [ORadj: 4.71 (3.14, 6.92)], 
respectively. Accounting for ZIP code tabulation area (ZCTA) of residence as a random 
effect in the multivariate model resulted in the best-fitting model.  
Conclusions: While accounting for known risk factors for PrCA, including age at 
diagnosis, Gleason score, TNM stage, and marital status, we found that residing more  
than 55 miles from the VA facility increased the risk for PrCA mortality. Outreach for 
screening, education and care coordination may be needed for veterans in these areas. 
4.2 Introduction 
In most men, prostate cancer (PrCA) is a relatively indolent disease, with an 
average mortality-to-incidence ratio of just 0.17 (i.e., 17% of all PrCA cases died of the 
disease) among White Americans in the US. However, there are considerable racial 
differences. For example, in South Carolina Black-American men have an MIR of 0.26 
(95% CI: 0.241-0.277) while their White-American counterparts have an MIR slightly 
lower than the national average (MIR = 0.16, 95% CI: 0.155-0.277).45 Because PrCA is the 
most common cancer among men2 and large racial disparities exist with respect to 
disease aggressiveness2, there is a clear clinical and scientific imperative to understand 
what drives PrCA burden. Risk factors for PrCA mortality include socioeconomic status 
(SES)6,9,11,81, residing in rural localities8, PrCA tumor Gleason score, and stage at 
diagnosis81. SES is a broad category that encompasses such factors as income and 
education level. Besides racial differences, PrCA mortality displays a spatial variation in 
the United States.38 The PrCA mortality rate in the US in 2014 was 19.1/ 100,000   
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men/year .82 This rate varied between the 50 states from a low of 14.4/100,000 
men/year in Hawaii to a high of 24.7 in Idaho.82 
Of all major racial groups in the United States, Blacks have the highest PrCA 
incidence and mortality. For example, in South Carolina, PrCA incidence in Blacks is 
about 80% higher than in Whites and mortality is over 2 ½ times higher.2,45 The United 
States Veteran’s Health Administration (VHA) provides a unique nationwide cohort of 
patients, namely veterans meeting certain eligibility criteria (e.g. served in the US armed 
forces and received a discharge other than dishonorable)83. SES factors such as 
education level, race and income that are typically associated with health outcomes in 
the United States are minimized within the VHA system since VHA care is not based on a 
fee-for-service arrangement and all eligible veterans have equal access to services. 
Veterans who receive VHA healthcare therefore become an ideal cohort to assess the 
impact of SES factors typically associated with access to healthcare or related factors, 
but have no apparent etiological link to that disease. Furthermore, recent developments 
in epidemiological modeling techniques allows public health researchers to evaluate 
multiple risk factors across multiple levels (e.g., individual and community) while also 
accounting for specific types of dependence in the data (e.g. spatial autocorrelation). In 
addition to these advantages, it is important to note that the VA system over-represents 
Blacks in the population84, and that South Carolina has one of the highest proportions 
(31%) of Black residents in the country85. 
This study seeks to identify individual and community-level risk factors 
associated with PrCA mortality, while also accounting for the unique (random effects)   
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and interdependent (autocorrelation) geographic context. The VHA system’s electronic 
medical records provide a nationwide comprehensive medical history of all veterans 
who receive care at all their facilities. We focused on South Carolina because its PrCA 
mortality rate is higher than the national rate82 yet is a being a smaller state by area 
with a large veteran population residing throughout the entire state and where the 
percent of Black veterans as part of the larger veteran population in SC is larger than the 
percent of Blacks in the general population.4,5 Because of its unique social and economic 
history, including historical context of slavery, South Carolina has the added advantage 
that Blacks live in all parts of the state, including rural areas. 
4.3 Methods 
4.3.1 Study Design 
This study employed a retrospective cohort design. The timeframe was from 01 
January 1999 to 31 December 2015. The unit of investigation was the US Census Bureau-
defined ZIP code tabulation areas (ZCTA), which consists of aggregated Zone 
Improvement Plan (ZIP) codes developed by the US Postal Service.63 All geographical 
related information was either linked to the shapefile (i.e. ZIP code patient level 
information linked to ZCTA’s in the shapefile), directly obtained at the ZCTA level (i.e. 
neighborhood-level information), or directly obtained from the 2015 ZCTA shapefile 
from the US Census Bureau (i.e. individual ZCTA boundaries).64 
4.3.2 Data Sources 
Data were obtained from the United States Department of Veteran Affairs and 
the United States Census Bureau. From the Unites States Department of Veteran Affairs   
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the following datasets were used: all MedSAS® datasets, Master Vital Status dataset, 
Mini Vital Status dataset, and Primary Oncology dataset from the VA Central Cancer 
Registry (VACCR).52,53 The VA Master Vital Status and VA Mini Vital Status datasets 
provided patient-level information (i.e., each unique VA patient is listed only once in 
these files) while the VA MedSAS® datasets provided visit-level information (i.e., with ≥1 
record/subject).52,53 From the United States Census Bureau the following datasets were 
used: United States 2010 Decennial Census, the 2007 – 2011 Five-Year American 
Community Survey, and the 2015 ZCTA shapefile for the US.4,5,64 
4.3.3 Exclusion Criteria 
Subjects were excluded based on the following criteria (see Figure 4.1 for the 
STROBE Diagram establishing the analytic cohort)65: data in the Primary Oncology 
Dataset from the VA Cancer Registry could not be linked to MedSAS® datasets52, a non-
prostate cancer diagnosis in the Primary Oncology Dataset from the VA Cancer Registry, 
prostate cancer diagnosis in the Primary Oncology Dataset from the VA Cancer Registry 
prior to January 1, 1999, date of birth differs by more than 365 days between VA 
MedSAS® datasets52 and VA Vital Status datasets53, age during the timeframe did not 
wholly or partially fall between 40 and 70 years old, missing ZIP code information, racial 
classification other than White or Black, not residing in a South Carolina ZIP code, not 
having a Gleason Score listed in the VACCR, missing PrCA diagnosis date, and negative 
time to event due to data entry error (e.g. diagnosis date occurred after date of death).  
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Overall, 964,047 unique subjects from a total of 1,159,188 (83.17%) unique 
cancer diagnoses were included in the Primary Oncology Dataset. Of these subjects, 
80.47% could be linked to unique patients in the MedSAS® datasets52. 
There were 235,782 unique PrCA cases in the Primary Oncology Dataset that 
could be linked to the VA MedSAS® Files52. There were 230,401 (97.72%) PrCA cases 
were exclude due to not residing in a South Carolina ZIP code. Of the 5,384 PrCA cases 
residing in a South Carolina ZIP code; 1,648 (30.61%) were ineligible due to diagnosis 
prior to 01/01/1999, date of birth discrepancy, age at first VA visit not satisfied, missing 
ZIP code, and/or not being White or Black,, 659 (12.2%) did not have a Gleason Score, 
three (0.06%) did not have a diagnosis date, and three (0.06%) had a negative time to 
event. The final analytical cohort consisted of 3,073 eligible South Carolina veterans 
with PrCA (Figure 4.1). 
4.3.4 South Carolina Geographical Area 
South Carolina veterans with PrCA that were not excluded resided in 346 of 
South Carolina’s 424 ZIP codes (81.6%). The 2015 ZCTA shapefile from the US Census  
Bureau was used South Carolina ZCTA’s were in turn used to link the selected ZCTA’s to 
ZIP codes with identical designations in the VA MedSAS® Files.52,63 
4.3.5 Time to Event Outcome 
Among subjects who died due to any cause, time in days between PrCA diagnosis 
and death was calculated for each subject using data from the VA Mini Vital Status 
dataset and the VACCR.53 Among subjects who were alive at the end of the study 
timeframe, time in days was calculated between PrCA diagnosis and the end of the   
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study timeframe (i.e. 12/31/2015). Subjects were considered right censored if they were 
alive at the end of the study. 
4.3.6 Individual-Level Independent Variables 
The date of the first VA visit for each subject was obtained from the MedSAS® 
datasets and the date of birth (DOB) was obtained from the VA Mini Vital Status 
dataset.52,53 Four age strata variables were created: age <40, age from 40 – 50, age from 
>50 – 60, age from >60 – 70 years. The information located within the VA Master Vital 
Status file for race and ethnicity were classified into White, Black, Hispanic, Asian, 
Hawaiian/Pacific Islander, and Native/Alaskan America, Other, and Unknown.53 Subjects 
other than White or Black racial category were exclude because they accounted for 
2.53% of the PrCA. The marital status field at the time of diagnosis in the Primary 
Oncology Dataset was used for PrCA cases. Marital status was categorized as Married, 
Previously Married (Divorced, Widowed, Separated), and Never Married/Unknown. The 
date of the first VA visit for each subject was obtained from the MedSAS® datasets and 
the date of PrCA diagnosis was obtained from the VACCR.52 Four age strata variables 
were created: age ≤50, age from >50 – 60, age from >60 – 70, age from >70 years. 
Gleason Scores for each subject was obtained from the VACCR.  
Gleason Scores were stratified into a dichotomous variable where a Gleason 
Score ≥7 was classified as high-risk and a Gleason Score of <7 was classified as low-risk. 
TNM Stages for each subject was obtained from the VACCR. TNM Staging was classified 
into Local, Regional, Distant, and Unknown. TNM Staging was also dichotomized into 
Distant and all other staging. The MedSAS® datasets were used to identify PrCA patients   
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with an International Classification of Disease version 9 Procedure Code for radical 
prostatectomy (i.e. 60.5).52 Radical prostatectomy was dichotomized into having 
received the procedure and not having received the procedure. The VACCR dataset was 
used to identify and PrCA patients who received hormone therapy for their treatment. 
PrCA patients were dichotomized into having received hormone therapy and not having 
hormone therapy. The VACCR dataset was used to identify PrCA patients who received 
radiation therapy for their treatment. PrCA patients were dichotomized into having 
received radiation therapy and not having radiation therapy. The VACCR dataset was 
used to identify PrCA patients who received chemotherapy for their treatment. PrCA 
patients were dichotomized into having received chemotherapy and not having 
chemotherapy.  
The modified Elixhauser Comorbidity Index was created excluding cancer 
diagnoses.86 Of the 32 comorbidities, two were excluded (any malignancy and 
metastatic solid tumor). The modified Elixhauser Comorbidity Index was used as a 
continuous variable indicating the number of unique comorbidities with a possible range 
of 0 to 30. A comorbidity was required to be listed on at least two distinct VA visits in 
the VA MedSAS® datasets.52  
The unique VA facility numerical codes in the MedSAS® datasets were used to 
identify which facility a subject visited.52 The number of different VA facilities used 
during the study timeframe, the most frequented VA facility during the study 
timeframe, and the number of times each subjected visited their most visited VA facility 
during the study timeframe were determined. The ZIP code listed the most times for   
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each subject’s total visits in the MedSAS® datasets was used for all ZIP code related 
information for each subject.52 For PrCA cases, the ZIP code at diagnosis was obtained 
from the Primary Oncology dataset. For PrCA cases, the ZIP code at diagnosis was used 
for cases without ZIP code information from the MedSAS® datasets (n = 6,784).52 
There were 131 unique VA facilities (i.e. VA hospitals and VA Community Based 
Outpatient Clinics) determined from VA MedSAS® datasets.52 The distance between the 
most frequented VA facility and ZCTA-linked ZIP code listed the most times was 
represented as a continuous variable and obtained using the MedSAS® datasets.52 This 
ZIP code information was linked to the 2015 ZCTA shapefile from the US Census 
Bureau.64 Using the shapefile, a contiguity straight line origin-to-destination matrix 
distance matrix between VA facilities and ZCTA code centroids to determine the 
distance traveled by a veteran to his most frequented VA facility.52,64 The distance 
between the most frequented VA facility and the ZCTA-linked ZIP code listed the most 
times was categorized into: 0 – 25 miles, >25 – 55 miles, and >55 miles. These cutoffs 
were selected a priori to represent how many miles can approximately be driven within 
30 minutes, 1 hour, and more than 1 hour. 
4.3.7 Neighborhood-Level Independent Variables 
The Social Vulnerability Index (SoVI®): The SoVI®, initially developed by the 
Hazards and Vulnerability Research Institute (HVRI) at the University of South Carolina, 
is a composite measure of neighborhood-level factors obtained from publicly available 
population based datasets of factors associated with the health of individuals within 
those neighborhoods.58 The SoVI®  uses ZCTA measurements obtained from the 2010 US   
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Census and the 2007 – 2011 5-Year American Community Survey.4,5 The SoVI® is a 
relative measure represented on a continuous scale from negative infinity to positive 
infinity in which the greater a geographical unit’s SoVI® score is the less prepared for, 
respond to, and recover from a disaster that area is compared to a geographical unit 
with a lower SoVI® score.66 A SoVI® score was assigned for each subject’s most 
frequently listed ZIP code. The SoVI® measurements were stratified into 3 categories 
using cutoffs of 1 standard deviations: Low (-∞, -2.04], Medium (-2.04, 2.79], and High 
(2.79, ∞). 
Specific Zip Code Level Factors: The 2007 – 2011 Five-Year American Community 
Survey was used to determine the percent of people within each ZIP code with at least a  
college degree with tertile cutoffs of [0%, 12.86%], [12.86%, 22.60%], [22.60%, 100%], 
percent of people within each ZIP code living in poverty with tertile cutoffs of [0%, 
7.96%], [7.96%, 15.86%], [15.86%, 100%], percent of Black Americans within each ZIP 
code with tertile cutoffs of: [0%, 0%], [0%, 2.73%], [2.73%, 100%], and percent of people 
within each ZIP code that were at least 65 years of age with tertile cutoffs of: [0%, 
11.95%], [11.95%, 16.92%], [16.92%, 100%].5 
4.3.8 Statistical Analyses 
Descriptive statistics were calculated for the analytical cohort. Kaplan-Meier 
curves were created to check the proportional hazards assumption for each variable. 
Chi-square tests and Fisher’s exact tests for categorical variables, and t-tests for 
continuous variables which used Gleason Score categories at the dependent variable 
were created.  
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Frequentist multivariate models using SAS® were first developed to inform key 
steps in development and evaluation of the final models.59 These models were 
developed for all individual level risk factors, and nested models incorporating both 
individual- and neighborhood-level risk factors with patient ZCTA-linked ZIP code 
residence as a random effect were created for model selection purposes. Bayesian 
models were developed for the null (empty) models; individual-level models; nested 
models incorporating both individual, area-level risk factors, and accounted for patient 
ZCTA-linked ZIP code residence as a random effect; and the multivariate conditional 
autoregressive models incorporating both individual, neighborhood-level risk factors, 
accounted for patient ZCTA residence as a random effect, and accounted for the spatial 
autocorrelation between ZCTA-linked ZIP codes using queen contiguity based spatial 
weights (i.e. all bordering ZCTAs for a given ZCTA.will have a weight of 1 while all other 
ZCTAs will have a weight of 0).34,36,37 
All categorical variables were evaluated using created dummy variables. Any 
independent individual-level variables where 95% confidence intervals could not be 
computed or extremely large point estimates with extremely wide 95% confidence 
intervals were excluded since those variables had almost all observations in one 
stratum. Independent individual-level variables not excluded were used in a manual 
backward stepwise approach to generate the final multivariate individual-level model 
were the added variable remained if it changed the risk factor estimates of the other  
variables by at least 10%. Multivariate models were created including and excluding 
PrCA stage.  
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A manual backward stepwise approach was used to determine the final nested-
level model. Each neighborhood level independent risk factor was evaluated separately 
with the final multivariate individual-level model. The model with the lowest Akaike 
information criterion (AIC) was selected as the initial nested-level model.67 
Subsequently, the neighborhood factor with the next lowest AIC was added to the initial 
nested-model. If any risk factor estimates changed by more than 10% than the 
additional neighborhood factor remained. This was repeated for all neighborhood level 
factors. 
The median odds ratio (MOR) was calculated for the unstructured variance when 
the model used ZIP codes as a random effect and was calculated for the structured 
variance when the model accounted for the spatial autocorrelation between ZCTA-
linked ZIP codes. The median odds ratio uses the specific aforementioned variances in 
the model and calculates a statistic that can be interpreted as the median difference in 
odds between the ZCTA-linked ZIP code with the highest compared to the lowest risk for 
two individuals with the same evaluated risk factors (i.e. the MOR is the risk estimate for 
the unexplained specific variation in the model).68 Therefore, the model with the best fit 
will also have the lowest MOR because risk factors in the model accounting for more of 
the variance in the outcome. 
A Global Moran I’s Test was conducted on the ZCTA-linked ZIP code level 
residuals of the final models to determine existence of spatial autocorrelation.37 If the  
Global Moran I’s Test was statistically significant, indicating the presence of spatial 
autocorrelation, then models accounting for spatial autocorrelation would be   
 
67 
constructed using risk factors included in the final nested-level models. If the Global 
Moran I’s Test was statistically nonsignificant, indicating no presence of spatial 
autocorrelation in the data, then the nested-level model would become the final overall 
model for that comparison. If the Global Moran I’s Test was statistically nonsignificant 
for the nested null model then the individual only level would be the final model. 
Based on the frequentist models, the final Bayesian models were developed. A 
Bayesian framework was selected for all final models because we assumed the factors 
associated ZIP code residence are not independent and random between neighboring 
ZIP codes and therefore will have a structured variance that needs to be accounted for. 
Incorporating a conditional autoregressive (CAR) component into the models is the most 
popular way to account for this structured variance. The most appropriate framework 
when incorporating a CAR component in the models is to use a Bayesian framework. It 
was decided prior to modeling building that since models incorporating a CAR 
component would have to be conducted in a Bayesian framework then all other final 
models would also be conducted within a Bayesian framework so as to compare 
between final models. 
All Bayesian models used uninformed priors. The initial statistical inference from 
each Bayesian model was based on 15,000 iterations (i.e. samples) after 5,000 burn-in 
period. The convergence of the sample chains was evaluated using the Geweke 
diagnostic, which compares the first 10% of kept iterations to the last 50% of kept  
iterations.69 The mean hazard ratio (HR) value was used as the point estimate for each 
individual and area level risk factors as well as the MOR estimates. The 2.5% and 97.5%   
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iteration cutoffs were used as the ranges for the 95% credible intervals (CrI) for each risk 
factor. 
Bayesian models created were compared to each other using the Deviation 
Information Criteria (DIC).60 The model with the lowest DIC was selected as the best-
fitting model for that comparison in that analytical cohort. 
4.3.9 Logistical Aspects 
All data storage, management, and analyses were conducted with the VA 
Informatics and Computing Infrastructure (VINCI) servers. All data management was 
done using Microsoft SQL Server. All univariate and frequentist modeling analyses were 
conducted using SAS® version 9.4 software.59 All Bayesian modeling was conducted 
using WinBUGS® version 1.4.3 and R version 3.3.2.60,61 All evaluation of Bayesian 
modeling was conducted using R.61 All statistical tests used an α-level of 0.05. This 
project had Institutional Review Board Approval from the University of South Carolina 
(Pro00036431) and the William Jennings Bryan Dorn VA (10404). 
4.4 Results 
There were 3,073 PrCA patients who met the inclusion criteria, and therefore 
comprise the analytical cohort. Of those, 534 (17.4%) died during the study timeframe. 
(Table 4.1) A slight majority of PrCA patients had a Gleason Score of at most a 6; 1,578 
(51.35%) while a large majority of PrCA patients had a localized tumor TNM stage; 2,803 
(91.21%) (Table 4.1). A majority of PrCA patients were Black (1,736 [56.49%]), married  
(1,767 [57.50%]), diagnosed with PrCA between > 60 – ≤ 70 (1,742 [56.69%]), travelled 
at most 55 miles to their most frequented VA facility (1,588 [51.68%]), did not receive   
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hormone therapy (2,268 [73.80%]), did not receive chemotherapy (3,067 [99.80%]), did 
not receive radiation therapy (1,703 [55.43%]), and did not have a radical prostatectomy 
(3,068 [99.84%]). 
4.4.1 Univariate Analyses 
There was a statistically significant difference in the average duration of the time 
accrued during the study timeframe between those that died (4.96 years) and those 
who survived (5.89 years) (Table 4.2). PrCA patients who died were statistically more 
likely to have a higher Modified Elixhauser Comorbidity Index (4.67 vs. 3.76), a higher 
Gleason score (60.11% vs. 46.27%), and more likely to have a TNM tumor stage of 
distant (5.81% vs. 0.87). (Table 4.2) PrCA patients who died were statistically less likely 
to have had radiation therapy (40.45% vs. 45.45%) but statistically more likely to have 
had hormone therapy (35.58% vs. 23.59%) (Table 4.2). PrCA patients who died were 
statistically less likely to have been diagnosed at a younger age (23.22% vs. 30.92%), less 
likely to have been married at the time of diagnosis (51.87% vs. 58.68%), and statistically 
more likely to travel more than 55 miles to their most frequented VA facility (55.06% vs. 
46.91%) (Table 4.2). The proportional hazards assumptions was satisfied for all 
independent risk factors. 
4.4.2 Multivariable Bayesian Modeling 
Two sets of seven models of increasing complexity using a Bayesian framework 
were fitted (Tables 4.3 – 4.4). One set included TNM tumor stage at the time of 
diagnosis (Table 4.3) while the other did not TNM tumor stage (Table 4.4). No ZCTA level   
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risk factors resulted in statistically significant additions to the individual level models 
during the frequentist model building phase. 
During the final Bayesian model building phase, all independent variables were 
significant for the first model in both sets. The second model was the nested null model 
where the subject’s ZIP code was accounted for as random effects. The third model 
accounted for the individual-level factors as well as nesting the subjects in their ZIP 
codes as random effects. The fourth model was the null model for the spatial 
autocorrelation between ZIP codes. Model 5 accounted for the individual level risk 
factors and the spatial autocorrelation between ZIP codes. Model 6 was the nested null 
model that accounted for the random effects of the ZIP codes and the spatial 
autocorrelation between ZIP codes. The final model, Model 7, accounted for the 
individual level risk factors, the random effects of the nested ZIP codes, and the spatial 
autocorrelation between ZIP codes. For both sets of models, Models 4 – 7 had the 
highest DIC’s (Tables 4.3 – 4.4). 
Model 3 had the lowest DIC for both sets of models with Model 3 from the first 
set (i.e. including TNM tumor stage) having the lowest DIC between the Model 3’s of the 
two sets. The individual level risk factors and the unstructured MOR for Model 3 in both 
sets were very similar. The final, best fitted model was Model 3 from the first set. 
PrCA patients were at increased risk of death if they were diagnosed later in life 
as compared to earlier in life (50 – 60 years of age): between > 60 and 70 years of age 
(HR: 1.65 [95%CrI: 1.35 – 2.04]) and greater than 70 years (HR: 2.34 [95%CrI: 1.80 –
3.02]). PrCA were at increased risk of death if the tumor Gleason Score was at least 7 as   
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compared to at most 6 (HR: 1.51 [95%CrI: 1.26 – 1.82]), and a TNM stage of distant (HR: 
4.71 [95%CrI: 3.14 – 6.92]) as compared to all other TNM staging. There was a  
protective association for PrCA patients receiving radiation therapy (HR: 0.66 [95%CrI: 
0.54 – 0.81]); however, PrCA patients were at increased risk of death if they received 
hormone therapy (HR: 1.31 [95%CrI: 1.07 – 1.60]). Not being married increased the risk 
of death among PrCA patients: for previously married (HR: 1.39 [95%CrI: 1.16 – 1.67]), 
and for PrCA patients who have never been married or their marital status in unknown 
(HR: 1.57 [95%CrI: 1.13 – 2.14]). PrCA patients who traveled more than 55 miles to their 
most frequented VA facility of care were at increased risk (HR: 1.25 [95%CrI: 1.04 – 
1.50]) as compared to PrCA patients who traveled at most 55 miles. Each additional 
comorbidity in the modified Elixhauser comorbidity index increased the risk of death 
(HR: 1.11 [95%CrI: 1.07 – 1.15]). The MOR for the unstructured variance of this model 
was 1.09 (95%CrI: 1.02 – 1.19) (Table 4.3). These results remained consistent when TNM 
tumor stage was removed from the model (Table 4.4). 
4.5 Discussion 
This study used an innovative approach to determine the potential impact of 
individual-level risk factors, area-level risk factors, and spatial autocorrelation on 
prostate cancer mortality within one modeling framework. The best fitting multivariate 
Bayesian model was Model 3 (Table 4.3), which controlled for individual level risk 
factors and accounted for ZCTA-linked ZIP code residence as a random effect. Our study 
identified an association between where a veteran lives and prostate cancer mortality.  
 
72 
We found that the ZCTA-linked ZIP code in which a veteran with PrCA resides 
had an effect on his mortality in two distinct ways. The first was that a veteran was at a 
25% increased risk of death if the distance traveled to his most frequented VA facility 
was more than 55 miles from his residence (Model 3 Table 4.3). This approximates to 
roughly a one-hour commute one way. This distance variable may also be considered as 
a component of the rural-urban divide that starkly characterizes SC, where all VA 
medical centers are located in the few urbanized localities, within the state while the SC 
veteran population who receive VA healthcare reside in nearly all the ZIP codes of the 
state. 
The second was that the ZCTA-linked ZIP code in which a veteran resides may 
increase the risk of mortality by approximately 9% (Model 3 Table 4.3). This is reflected 
in the median odds ratio (MOR) for the model. This MOR indicates that there are ZCTA-
linked ZIP code-level factors that are not accounted for in the model which results in a 
cumulative median increased risk between the ZCTA-linked ZIP code with the highest 
mortality as compared to the ZCTA-linked ZIP code with lowest mortality for veterans 
with identical individual level factors that were measured. This result is of unique 
interest since several ZCTA-linked ZIP code level factors as well as the SoVI® (which is a 
composite measure of 30 ZIP code level factors) were evaluated during the model 
building phase of this study and were found to not be associated with PrCA mortality 
when the individual level factors were accounted for. This may indicate the potential for 
at least one unmeasured ZIP code-level factor that could influence PrCA mortality.  
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Additionally, each increase of the modified Elixhauser Comorbidity Index score 
increases the risk of mortality for veterans with PrCA by 11% (Model 3, Table 4.3). This is 
expected because the modified Elixhauser Comorbidity Index score reflects how sick a 
patient is with comorbid chronic diseases that also might affect mortality. 
Our best-fitting model confirms established risk factors for PrCA mortality. These 
include increasing mortality risk with increased age87, a Gleason score of at least 787, a 
TMN stage of distant2, and a protective effect against mortality of being married88 
(Model 3 Table 4.3). Under further investigation, while veterans with PrCA were 4.71 
times more likely to die with a TNM stage of distant; removal of TNM stage from the 
model did not alter: 1) the best-fitting model, 2) the remaining risk factors that comprise 
the best-fitting model, and 3) the risk estimates and 95% credible intervals of the 
remaining risk factors by a significant amount (Tables 4.3 – 4.4). 
Furthermore, receiving radiation therapy was a protective effect while receiving 
hormone therapy was a risk factor of PrCA mortality. (Model 3 Table 4.3) These two 
results should be considered as confounding by indication; i.e. these therapies reflect 
the aggressiveness of the PrCA tumor which directly impacts patient mortality rather 
than the therapies themselves “increasing” or “decreasing” risk of mortality. Clinically, a 
more aggressive PrCA tumor will be treated by hormone therapy while a less aggressive 
tumor will be monitored and/or begun on radiation therapy. It should also be noted that 
these estimates did not differ when TMN staging was removed from the models. (Model 
3 Table 4.4) This occurrence may possibly reflect the clinical practice that for PrCA 
patients TNM staging is not as critical in dictating treatment.  
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Being Black is a known risk factor for PrCA mortality2,45; however, in all the 
multivariate Bayesian models, being black was not a risk factor in assessing PrCA 
mortality among South Carolina veterans seeking care at VA facilities. (Tables 4.3 – 4.4). 
This was initially seen in the Kaplan-Meier curves were there was not a statistically  
significant difference between White and Black. This was reinforced in the univariate 
analyses (Table 4.2). One possible explanation is that while being Black is a risk factor for 
developing PrCA2,45; after diagnosis, whatever latent risk factors in racial categorization 
that impact PrCA mortality are 1) societal in nature and not biological and 2) those 
factors are minimized in SC veterans with PrCA due to equalizing access to healthcare in 
the VHA population. This observation should further be replicated again in veteran 
populations who receive VA care in other states. 
4.5.1 Strengths and Limitations 
Limitations exist in the use of electronic medical records for retrospective 
observational studies.74 However, the VA electronic medical records have been 
extensively used for such studies.75-78 
In regards to this study, it is most problematic when matching ZCTA’s and ZIP 
codes for areas without populations.79 The VHA electronic medical records provides 
patient ZIP code information while the US Census provides shapefiles using ZCTA’s. 
While ZCTA’s approximate the shape of ZIP codes; ZCTA’s are not a perfect match for ZIP 
codes and ZCTA’s are not updated when ZIP codes change shape or new ZIP codes are 
added. However, limiting the population under investigation to South Carolina, which is 
a small, stably-populated state as compared to the rest of the nation should mitigate   
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the boundary issue (i.e. changing ZIP code shapes) as well as the addition of new ZIP 
codes. Therefore, the only areas impacted by boundary issues are those ZCTAs 
bordering the states of Georgia and North Carolina, which is always present in all spatial 
analyses where there is an adjacent area not included in the analysis, which is known as 
the edge effect.89  
The 2015 ZCTA shapefile for South Carolina was chosen because it was created 
during the last year of the study timeframe.64 However, the study timeframe was wide, 
ranging from 1999 to 2015. ZCTA shapefiles for other years were excluded because 
utilizing the most recent shapefile possible would also account for additions in SC ZCTA’s 
but not deletions, which are rarer then additions. Ultimately, conducting a spatial 
analysis over multiple years using geographical units that have the potential to change 
will continue to pose such issues. What needs to be considered is how those changes 
impact the study. For this reason, as was previously mentioned, SC has a small and 
stable population, which would minimize any changes (both major and minor) in the 
shapes of ZCTA’s across the study timeframe. 
South Carolina veterans who did not meet the exclusion criteria and seek 
healthcare at a VA facility not in South Carolina were still included in the analyses. 
Receiving care at a South Carolina VA facility was not an exclusion criterion for that 
reason. The closet VA healthcare facility may be located across the state line for many  
border areas of the South Carolina. This occurrence does not impact the analyses in 
determining if residence-specific characteristics are associated with PrCA.  
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Interestingly, the use of ZCTA. which spread the distribution of 3,073 PrCA cases 
among 346 ZIP codes, is a possible explanation of why accounting for the spatial 
autocorrelation results in large DIC’s because the spatial autocorrelation component of 
the model is only accounting for background variation. 
More importantly, the ZCTA-linked ZIP code was selected as the geographical 
unit of analysis because it was the most appropriate choice to assess the spatial impact 
of prostate cancer epidemiology for two reasons. The first is that it was the smallest of 
the two geographical units available (the other being county). The second is a 
consequence of the first reason. The more homogenous the population was, the more 
likely to differentiate between ZCTA-linked ZIP codes in the models and therefore 
identify ZCTA-linked ZIP codes with higher and lower than expected risks for PrCA. As 
the geographical unit area increases, the population becomes more heterogeneous in 
characteristics that could not be assessed. This increases the likelihood of introducing an 
unaccounted-for directional bias. 
Finally, all-cause mortality was selected instead of cause-specific (i.e. PrCA-
specific) mortality because this was an initial evaluation in accounting for spatial factors 
in multivariate survival models for PrCA. The next phase will be to evaluate the data 
using cause-specific mortality as the outcome of primary interest. 
In closing, we were able to 1) confirm established risk factors (e.g. age at 
diagnosis, marital status, Gleason Score, and TNM stage), 2) identify that modeling 
radiation and hormone therapy is probably confounding by indication, and 3)   
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demonstrate that where a veteran resides does influence PrCA mortality with the South 





Table 4.1. Descriptive statistics of South Carolina veteran population who were treated for prostate cancer at Veteran Health 
Administration facilities from January 1, 1999 to December 31, 2015 and meet the study inclusion criteria 
 
Categorical Variables N = 3,073 (%) 
Mortality Status  
Alive 2,539 (82.62) 
Dead 534 (17.38) 
Prostate Cancer Gleason Score  
High Risk (Gleason Score ≥ 7) 1,495 (48.65) 
Low Risk (Gleason Score < 7) 1,578 (51.35) 
Prostate Cancer Stage Category 1  
Local 2,803 (91.21) 
Regional 170 (5.53) 
Distant 53 (1.72) 
Unknown 47 (1.53) 
Prostate Cancer Stage Category 2  
Distant 53 (1.72) 
Non-Distant 3,020 (98.28) 
Age at First VA Visit  
< 40 28 (0.91) 
40 – 50 448 (14.58) 
>50 – 60 1,451 (47.22) 
>60 – 70 1,146 (37.29) 
Race  
White 1,337 (43.51) 
Black 1,736 (56.49) 
Marital Status  
Married 1,767 (57.50) 
Ever Married 1,035 (33.68) 
Never Married /Unknown 271 (8.82) 
Radical Prostatectomy  
Yes 5 (0.16) 




Radiation Therapy  
Yes 1,370 (44.58) 
No 1,703 (55.43) 
Chemotherapy  
Yes 6 (0.20) 
No 3,067 (99.80) 
Hormone Therapy  
Yes 805 (26.20) 
No 2,268 (73.80) 
Distance Category 1 (miles)  
≤ 25 860 (27.99) 
> 25 – 55 728 (23.69) 
> 55 1,485 (48.32) 
Distance Category 2 (miles)  
≤ 55 1,588 (51.68) 
> 55 1,485 (48.32) 
Age at Prostate Cancer Diagnosis Category 1 (years)  
≤ 50 76 (2.47) 
> 50 – 60 833 (27.11) 
> 60 – 70 1,742 (56.69) 
> 70 422 (13.73) 
Age at Prostate Cancer Diagnosis Category 2 (years)  
≤ 60 909 (29.58) 
> 60 – 70 1,742 (56.69) 
> 70 422 (13.73) 
Continuous Variable Mean (Standard Deviation) Median (Minimum, Maximum) 
Time in Study (years) 5.73 (3.55) 5.17 (<0.01, 15.88) 






Table 4.2. Univariate comparisons between censored status and risk factors among South Carolina veteran population who 
were treated for prostate cancer at Veteran Health Administration facilities from January 1, 1999 to December 31, 2015 and meet 
the study inclusion criteria 
 
Categorical Variables Died; n = 534 (%) Alive; n = 2,539 (%) p-value 
Prostate Cancer Gleason Score    
High Risk (Gleason Score ≥ 7) 321 (60.11) 1,174 (46.27) <0.01 
Low Risk (Gleason Score < 7) 213 (39.89) 1,365 (53.76)  
Prostate Cancer Stage Category 1    
Local 456 (85.39) 2,347 (92.44) <0.01 
Regional 39 (7.30) 131 (5.16)  
Distant 31 (5.81) 22 (0.87)  
Unknown 8 (1.50) 39 (1.54)  
Prostate Cancer Stage Category 2    
Distant 31 (5.81) 22 (0.87) <0.01 
Non-Distant 503 (94.19) 2,517 (99.13)  
Age at First VA Visit    
< 40 1 (0.19) 27 (1.06) <0.01 
40 – 50 38 (7.12) 410 (16.15)  
>50 – 60 210 (39.33) 1,241 (48.88)  
>60 – 70 285 (53.37) 861 (33.91)  
Race    
White 267 (50.00) 1,070 (42.14) <0.01 
Black 267 (50.00) 1,469 (57.86)  
Marital Status    
Married 277 (51.87) 1,490 (58.68) 0.01 
Ever Married 207 (38.76) 828 (32.61)  
Never Married /Unknown 50 (9.36) 221 (8.70)  
Radical Prostatectomy    
Yes 0 (0) 5 (0.20) 0.38 
No 534 (100) 2,534 (99.80)  
Radiation Therapy    




No 318 (59.55) 1,385 (54.55)  
Chemotherapy    
Yes 2 (0.37) 4 (0.16) 0.21 
No 532 (99.63) 2,535 (99.84)  
Hormone Therapy    
Yes 206 (38.58) 599 (23.59) <0.01 
No 328 (61.42) 1,940 (76.41)  
Distance Category 1 (miles)    
≤ 25 130 (24.34) 730 (28.75) <0.01 
> 25 – 55 110 (20.60) 618 (24.34)  
> 55 294 (55.06) 1,191 (46.91)  
Distance Category 2 (miles)    
≤ 55 240 (44.94) 1,348 (53.09) <0.01 
> 55 294 (55.06) 1,191 (46.91)  
Age at Prostate Cancer Diagnosis 
Category 1 (years) 
   
≤ 50 9 (1.69) 67 (2.64) <0.01 
> 50 – 60 115 (21.54) 718 (28.28)  
> 60 – 70 295 (55.24) 1,447 (56.99)  
> 70 115 (21.54) 307 (12.09)  
Age at Prostate Cancer Diagnosis 
Category 2 (years) 
   
≤ 60 124 (23.22) 785 (30.92) <0.01 
> 60 – 70 295 (55.24) 1,447 (56.99)  
> 70 115 (21.54) 307 (12.09)  
Continuous Variables Mean (95% Confidence Interval) Mean (95% Confidence Interval)  
Time in Study (years) 4.96 (4.67, 5.23) 5.89 (5.75, 6.03) <0.01 








Table 4.3. Hazard ratios and 95% credible intervals for multivariate models that included prostate cancer tumor classification 
among South Carolina veteran population who were treated for prostate cancer at Veteran Health Administration facilities from 
January 1, 1999 to December 31, 2015 and meet the study inclusion criteria 
 
Risk Factors Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7 
Age at Diagnosis        
     50 – 60  Reference  Reference  Reference  Reference 
     >60 – 70 1.67 (1.34 – 2.08)  1.65 (1.35 – 2.04)  1.35 (1.25 – 1.47)  1.36 (1.25 – 1.48) 
     >70 2.36 (1.82 – 3.09)  2.34 (1.80 – 3.02)  1.31 (1.16 – 1.47)  1.32 (1.17 – 1.48) 
Gleason Score ≥7 1.51 (1.24 – 1.82)  1.51 (1.26 – 1.82)  1.17 (1.08 – 1.26)  1.17 (1.08 – 1.26) 
Distant Stage 4.72 (3.12 – 6.83)  4.71 (3.14 – 6.92)  1.86 (1.38 – 2.47)  1.87 (1.40 – 2.48) 
Radiation Therapy 0.66 (0.55 – 0.80)  0.66 (0.54 – 0.81)  0.86 (0.79 – 0.93)  0.86 (0.79 – 0.93) 
Hormone Therapy 1.31 (1.07 – 1.60)  1.31 (1.07 – 1.60)  0.94 (0.86 – 1.03)  0.94 (0.86 – 1.03) 
Marital Status        
     Married Reference  Reference  Reference  Reference 
     Previously Married 1.40 (1.17 – 1.68)  1.39 (1.16 – 1.67)  1.14 (1.06 – 1.23)  1.14 (1.06 – 1.23) 
     Never Married/Unknown 1.58 (1.15 – 2.14)  1.57 (1.13 – 2.14)  1.24 (1.08 – 1.40)  1.24 (1.09 – 1.41) 
Travelled > 55 Miles 1.25 (1.06 – 1.46)  1.25 (1.04 – 1.50)  0.99 (0.91 – 1.09)  1.00 (0.91 – 1.11) 
Modified Elixhauser Comorbidity Index 1.11 (1.08 – 1.15)  1.11 (1.07 – 1.15)  0.97 (0.96 – 0.99)  0.97 (0.96 – 0.99) 
Median Odds Ratio (unstructured variance) NA 1.08 (1.02 – 1.18) 1.09 (1.02 – 1.19) NA NA 1.02 (1.01 – 1.03) 1.00 (1.00 – 1.01) 
Median Odds Ratio (structured variance) NA NA NA 1.03 (1.01 – 1.05) 1.02 (1.00 – 1.04) 1.03 (1.01 – 1.05) 1.02 (1.00 – 1.04) 
Deviance 10,821.60 11,037.88 10,818.82 52,408.41 52,277.65 52,391.46 52,271.10 
Bayesian        
Iterations 40,000 40,000 20,000 20,000 40,000 40,000 20,000 
Burn–in 15,000 15,000 5,000 5,000 15,000 15,000 5,000 
Thinning 10 1 1 1 1 1 5 
Model 1: Individual Level Risk Factors Only; Model 2: Nested Null Model (Unstructured Variance; Random Effects); Model 3: Nested Model with Individual Level Risk Factors (Unstructured Variance; Random Effects); Model 4: 
Nested Null Model (Structured Variance; CAR Model); Model 5: Nested Model with Individual Level Risk Factors (Structured Variance; CAR Model); Model 6: Nested Null Model (Unstructured and Structured Variance; Random 




Table 4.4. Hazard ratios and 95% credible intervals for multivariate models that did not include prostate cancer tumor 
classification among South Carolina veteran population who were treated for prostate cancer at Veteran Health Administration 
facilities from January 1, 1999 to December 31, 2015 and meet the study inclusion criteria 
 
Risk Factors Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7 
Age at Diagnosis        
     50 – 60  Reference  Reference  Reference  Reference 
     >60 – 70 1.66 (1.35 – 2.04)  1.65 (1.34 – 2.06)  1.35 (1.25 – 1.47)  1.35 (1.25 – 1.47) 
     >70 2.78 (1.77 – 2.94)  2.26 (1.74 – 2.93)  1.30 (1.16 – 1.47)  1.30 (1.16 – 1.46) 
Gleason Score ≥7 1.55 (1.29 – 1.86)  1.55 (1.30 – 1.85)  1.18 (1.09 – 1.27)  1.18 (1.09 – 1.27) 
Distant Stage NA  NA  NA  NA 
Radiation Therapy 0.60 (0.50 – 0.71)  0.60 (0.50 – 0.72)  0.84 (0.76 – 0.91)  0.84 (0.78 – 0.91) 
Hormone Therapy 1.49 (1.23 – 1.81)  1.48 (1.22 – 1.79)  0.97 (0.88 – 1.06)  0.97 (0.87 – 1.06) 
Marital Status        
     Married Reference  Reference  Reference  Reference 
     Previously Married 1.37 (1.15 – 1.64)  1.38 (1.15 – 1.66)  1.14 (1.05 – 1.23)  1.14 (1.06 – 1.24) 
     Never Married/Unknown 1.53 (1.12 – 2.04)  1.54 (1.14 – 2.09)  1.23 (1.08 – 1.40)  1.24 (1.08 – 1.40) 
Travelled > 55 Miles 1.28 (1.07 – 1.53)  1.26 (1.07 – 1.48)  0.99 (0.90 – 1.09)  0.99 (0.89 – 1.09) 
Modified Elixhauser Comorbidity Index 1.10 (1.06 – 1.13)  1.09 (1.06 – 1.14)  0.97 (0.96 – 0.99)  0.97 (0.96 – 0.99) 
Median Odds Ratio (unstructured variance) NA 1.08 (1.02 – 1.18) 1.07 (1.02 – 1.18) NA NA 1.02 (1.01 – 1.03) 1.00 (1.00 – 1.01) 
Median Odds Ratio (structured variance) NA NA  1.03 (1.01 – 1.05) 1.02 (1.00 – 1.04) 1.03 (1.01 – 1.05) 1.01 (1.00 – 1.04) 
Deviance 10,863.44 11,037.88 10,861.33 52,408.41 52,293.97 52,391.46 52,290.60 
Bayesian        
Iterations 60,000 40,000 60,000 20,000 20,000 40,000 40,000 
Burn–in 30,000 15,000 30,000 5,000 5,000 15,000 15,000 
Thinning 10 1 5 1 5 1 1 
Model 1: Individual Level Risk Factors Only; Model 2: Nested Null Model (Unstructured Variance; Random Effects); Model 3: Nested Model with Individual Level Risk Factors (Unstructured Variance; Random Effects); Model 4: 
Nested Null Model (Structured Variance; CAR Model); Model 5: Nested Model with Individual Level Risk Factors (Structured Variance; CAR Model); Model 6: Nested Null Model (Unstructured and Structured Variance; Random 













































Figure 4.1. STROBE Diagram for the generation of the analytical cohort for survival 
modeling among the South Carolina veteran population with prostate cancer who seek 
healthcare at Veteran Health Administration facilities from January 1, 1999 to December 
31, 2015 and meet the study inclusion criteria 
 
964,047 unique patients in VA Cancer Registry 
775,769 unique patients in both VA Cancer Registry and VA MedSAS® Files 
235,782 prostate cancer patients 
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5,384 prostate cancer patients in South Carolina 
3,073 eligible prostate cancer patients in South Carolina 
917 prostate cancer diagnosis before 1/1/1999 
6 date of birth difference greater than 1 year between datasets 
1,178 age out of range
 103 not White or Black
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Prostate Cancer Mortality-to-Incidence Ratios Among South Carolina Veterans: 1999 – 
2015 
5.1 Abstract 
Background: The mortality-to-incidence ratio (MIR) is an established 
epidemiological measure that approximates one minus survival and therefore is a valid 
approximation of frailty. Use of MIRs in recent years has helped to describe virulence of 
cancer in specific populations. A key feature of the MIR is its ability to be used to 
compare cancers across different populations. This study describes prostate cancer 
MIRs in the South Carolina (SC) veteran population from 1999 to 2015. 
Methods: US Veterans Health Administration electronic medical records from 
January 1999 to December 2015, were used to identify 3,073 PrCA patients residing in 
346 ZIP codes within SC. An overall MIR was calculated along with MIRs stratified by key 
prostate cancer risk factors and neighborhood risk factors. PrCA MIRs were also 
computed for ZIP code tabulation areas (ZCTA) in which veterans resided. Global and 
local Moran I statistics were computed to examine spatial clustering of MIRs across SC 
ZCTAs. 
Results: The overall PrCA MIR in this population was 0.17. The MIR was 0.15 
among Blacks, 0.20 among Whites, 0.16 among men who were married at PrCA 
diagnosis, 0.18 in men residing in a metropolitan ZCTA, and 0.16 in men residing in a 
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non-metropolitan ZCTA. Collectively, MIRs did not vary spatially by ZCTAs. Two ZCTA 
clusters of higher than expected MIRs were found in the upstate region. 
Conclusions: The overall MIR was lower than for the population as a whole. This 
is the first known report showing that the MIR was lower among Blacks than Whites 
(25% lower as opposed to 59% higher in the US as a whole). The PrCA MIR among 
veterans during the study timeframe varied across key risk factor strata for PrCA. Also, 
geographically, statistically significant clusters MIRs were found. Application of the MIR 
in this context revealed that veterans, on average, have lower mortality given incidence 
than in the population as a whole and that Blacks have a MIR which is much lower (i.e., 
by 38%) than for the country as a whole. Additional work is needed to understand the 
reason for these differences. 
5.2 Introduction 
The mortality-to-incidence ratio (MIR) for cancers has been established to be a 
valid approximation of the 5-year frailty measure, which is the equivalent of 1-survival 
estimate.90,91 Use of the MIR to describe cancer virulence is becoming more popular 
among health scientists due to the relative ease of computing MIRs, as opposed to 
obtaining the requisite data to compute survival or frailty.44,45,90-101 A key feature of the 
MIR is that cancer cases do not have to be followed individually. The only information 
required is the number of new cancer cases and the number of individuals with that 
same cancer who died in a specific timeframe. The cancer MIR is an important measure 
that can be used for both descriptive and inferential comparisons.44,45,92-101 This utility of 
the MIR for epidemiological cancer research allows scientists to describe and   
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understand how a specific cancers affect the general population and how these factors 
may vary in key subgroups or segments of population. 
The United States (US) Veterans Health Administration (VHA) has an electronic 
health records database that affords researchers a robust source of important clinical 
data for a unique segment of the population. The information in the VHA electronic 
medical records is standardized for the entire US making it the largest such repository in 
the US. Another important and unique feature of the VHA is that it is not a fee-for-
service healthcare enterprise. Therefore, financial considerations associated with 
healthcare utilization are minimized for veterans who qualify to receive care at the VHA. 
Prostate cancer (PrCA) is an important cancer to investigate for two reasons. The 
first is that PrCA is the most common epithelial cancer among men in the US, accounting 
for 19% of all new cancers in 2018 while only accounting for 9% of all cancer mortality 
during 2018.2 This difference between PrCA incidence and mortality has led to the 
colloquial but accurate statement that an “individual with PrCA is more likely to die with 
it than due to it”. The second reason is that large differences exist in both PrCA 
incidence and mortality rates between Whites and Blacks and across different age 
groups.2 By better understanding the epidemiology of PrCA in various groups can begin 
to minimize if not eliminate these disparities. The study of PrCA among veterans 
becomes more important since as of 2015, nationally males comprise 86.89% of the 
veteran population and 89.98% in South Carolina (SC).102 
This study was designed to describe and evaluate PrCA MIRs among SC veterans 
who receive care at VHA facilities. SC was chosen because of its small geographical size   
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relative to other states, high representation by Black Americans, and its stable veteran 
population. Overall PrCA MIRs for all veterans and by key subgroups was determined. 
Additionally, we sought to evaluate geospatial differences in veteran MIRs by ZIP code 
tabulation areas (ZCTAs). 
5.3 Methods 
5.3.1 Study Design 
This study employed a retrospective cohort design. The timeframe was from 01 
January 1999 to 31 December 2015. The geographical unit of investigation was the 
ZCTA, which the US Census Bureau develops every ten years by aggregating Census 
blocks whose addresses have a common Zone Improvement Plan (ZIP) code.64 
5.3.2 Data Sources 
Data were obtained from the US Department of Veteran Affairs and the U.S 
Census Bureau. From the US Department of Veteran Affairs the following datasets were 
used: all MedSAS® datasets, Master Vital Status dataset, Mini Vital Status dataset, and 
Primary Oncology dataset from the VA Central Cancer Registry (VACCR).52,53 The VA 
Master Vital Status and VA Mini Vital Status datasets provided patient-level information 
(i.e., each unique VA patient is listed only once in these files) while the VA MedSAS® 
datasets provided visit-level information (i.e., with ≥1 record/subject).52,53 From the US 
Census Bureau the 2015 ZCTA shapefile for the US was obtained.64 
5.3.3 South Carolina Geographical Area 
Eligible South Carolina veterans with PrCA resided in 346 of South Carolina’s 424 
ZIP codes (81.6%). The 2015 ZCTA shapefile from the US Census Bureau was used. South   
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Carolina ZCTAs were in turn used to link the selected ZCTAs to patient’s ZIP codes with 
identical designations in the VA MedSAS® Files.52,64  
5.3.4 Exclusion Criteria 
Subjects were excluded based on the following criteria (see Figure 4.1 for the STROBE 
Diagram establishing the analytic cohort): data in the Primary Oncology Dataset from 
the VA Cancer Registry could not be linked to MedSAS® datasets52, a non-PrCA diagnosis 
in the Primary Oncology Dataset from the VA Cancer Registry, PrCA diagnosis in the 
Primary Oncology Dataset from the VA Cancer Registry prior to January 1, 1999, date of 
birth differs by more than 365 days between VA MedSAS® datasets52 and VA Vital Status 
datasets53, age during the timeframe did not wholly or partially fall between 40 and 70 
years old, missing ZIP code information, racial classification other than White or Black 
because those racial classifications accounted for 2.53% of the PrCA patients, not 
residing in a SC ZIP code, missing Gleason Score listed in the VACCR, missing PrCA 
diagnosis date, and negative time to event due to data entry error (e.g., diagnosis date 
occurred after date of death). 
Overall, 964,047 unique subjects from a total of 1,159,188 (83.17%) unique 
cancer diagnoses were included in the Primary Oncology Dataset. Of these subjects, 
80.47% could be linked to unique patients in the MedSAS® datasets.52 
There were 235,782 unique PrCA cases in the Primary Oncology Dataset that 
could be linked to the VA MedSAS® Files. There were 230,401 (97.72%) PrCA cases 
excluded due to not residing in a SC ZIP code or have a missing ZIP code. Of the 5,384 
PrCA cases residing in a SC ZIP code; 1,648 (30.61%) were ineligible due to diagnosis   
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prior to 01/01/1999, date of birth discrepancy, age at first VA visit not satisfied, and/or 
not being White or Black, 659 (12.2%) did not have a Gleason Score, three (0.06%) did 
not have a diagnosis date, and three (0.06%) had a date of death prior to their date of 
PrCA diagnosis. The final analytical cohort consisted of 3,073 eligible SC veterans with 
PrCA (Figure 5.1). 
5.3.5 Mortality-to-Incidence Ratio Calculations 
The overall MIR for PrCA in SC among Black and White veterans who sought 
healthcare at VHA facilities was calculated as the number of those cases who died due 
to PrCA according to the VACCR divided by the number of PrCA cases in the VACCR.45 
MIRs have a minimum value of 0 (i.e. no death for the disease of interest among 
everyone with the disease during the timeframe of interest) to 1 (i.e. everyone died for 
the disease of interest among everyone with the disease during the timeframe of 
interest). Stratified PrCA MIRs (e.g., by socio-economic status) for this cohort were 
calculated using the same calculation. 
5.3.6 Stratified Mortality-to-Incidence Ratios for Individual-Level Variables 
Age at First VA Visit: The date of the first VA visit for each subject was obtained 
from the MedSAS® datasets and the date of birth (DOB) was obtained from the VA Mini 
Vital Status dataset.52 Four age strata variables were created: age <40 years, age from 
40 – 50 years, age from >50 – 60 years, age from >60 – 70 years. The number of PrCA 
cases and the number of deaths among these PrCA cases were aggregated by each 
stratum to calculate the MIR for each age at first VA visit strata.  
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Race-Related Variable: The information located within the VA Master Vital Status 
file for race and ethnicity were classified into White, Black, Hispanic, Asian, 
Hawaiian/Pacific Islander, and Native/Alaskan America, Other, and Unknown.53 The 
numbers of PrCA cases and deaths among these PrCA cases were aggregated by each 
stratum to calculate the MIR for each racial strata. 
Marital Status-Related Variable: The marital status at the time of diagnosis 
(obtained from the VACCR) was categorized as Married, Previously Married (Divorced, 
Widowed, Separated), and Never Married/Unknown. The number of PrCA cases and the 
number of deaths among these PrCA cases were aggregated to calculate the MIR for the 
marital status strata. 
5.3.7 Stratified Mortality-to-Incidence Ratios for Neighborhood -Level Variables 
The Social Vulnerability Index (SoVI®): The SoVI®, initially developed by the 
Hazards and Vulnerability Research Institute (HVRI) at the University of South Carolina, 
is a composite measure of neighborhood-level factors obtained from publicly available 
population based datasets of factors associated with the health of individuals within 
those neighborhoods.58 The SoVI®  uses ZCTA measurements obtained from the 2010 US 
Census and the 2007 – 2011 5-Year American Community Survey.4,5 The SoVI® is a 
relative measure represented on a continuous scale from negative infinity to positive 
infinity in which the greater a geographical unit’s SoVI® score is the less prepared for, 
able to respond to, and able to recover from a disaster in that area compared to a 
geographical unit with a lower SoVI® score.66 A SoVI® score was assigned for each 
patient’s ZIP code listed at the time of PrCA diagnosis. The SoVI® measurements were   
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stratified into 3 categories using cutoffs of 1 standard deviations: Low (-∞, -2.04], 
Medium (-2.04, 2.79], and High (2.79, ∞). The number of PrCA cases and the number of 
deaths among these PrCA cases were aggregated to calculate the MIR for the SoVI® 
strata. 
Rural-Urban Community Area (RUCA) classification: The RUCA is a measure of 
how rural an area is. Originally developed by the Economic Research Service, which is 
part of the US Department of Agriculture.103 The RUCA was initially determined for 
states, counties, and census tracts.103 The WWAMI Rural Health Research Center at the 
University of Washington extended the RUCA to include ZIP codes.104 The SC ZIP code 
RUCA from the University of Washington was merged with ZCTA measurements 
obtained from the US Census Bureau.64,104 Every ZCTA-linked ZIP codes with PrCA cases 
were able to link to the corresponding RUCA ZIP code. The ZIP code-level RUCA was 
stratified into metropolitan and non-metropolitan classifications for each ZCTA. The 
number of PrCA cases and the number of deaths among these PrCA cases were 
aggregated by each RUCA stratum to calculate the MIR for each RUCA strata. 
5.3.8 Descriptive Spatial Analyses 
MIRs for each ZCTA were plotted on the SC map obtained from the US Census 
Bureau using R to create a choropleth map of SC PrCA MIRs by ZCTA among SC veterans 
(Figure 5.2).61,64 A global Moran’s I was calculated to determine whether there is overall 
spatial randomness among MIRs across SC ZCTAs.37 A local Moran’s I was calculated and 




There were 3,073 PrCA cases in the VACCR in SC from January 1, 1999 to 
December 31, 2015. Of those, 534 died during that time where the cause of death was 
directly attributed to PrCA. This resulted in an overall MIR of 0.17. There were 1,337 
Whites with PrCA and 267 deaths among White SC veterans due to PrCA, for a MIR of 
0.20 (Figure 5.2). There were 1,736 Blacks with PrCA were 267 deaths among Black SC 
veterans due to PrCA for an MIR of 0.15. Among veterans who had their first VA visit 
prior to 40 years of age, there were 28 PrCA cases with 1 death due to PrCA for a MIR of 
0.04. Among veterans who had their first VA visit between 40 and 50 years of age, there 
were 448 PrCA cases with 38 deaths due to PrCA for a MIR of 0.08. Among veterans who 
had their first VA visit between after 50 and 60 years of age, there were 1,451 PrCA 
cases with 210 deaths due to PrCA for a MIR of 0.14. Among veterans who had their first 
VA visit between after 60 and 70 years of age, there were 1,146 PrCA cases with 285 
deaths due to PrCA for a MIR of 0.25. There were 1,767 PrCA cases who were married at 
the time of diagnosis of which 277 died due to PrCA for a MIR among married SC 
veterans of 0.16. Among ZCTAs whose had the lowest SoVI® values, there were 168 
PrCA cases with 22 deaths due to PrCA for a MIR among the ZCTAs with the lowest 
SoVI® values of 0.13. Among ZCTAs whose had the medium SoVI® values, there were 
2,342 PrCA cases with 426 deaths due to PrCA for a MIR among the ZCTAs with medium 
SoVI® values of 0.18. Among ZCTAs whose had the highest SoVI® values, there were 563 
PrCA cases with 86 deaths due to PrCA for a MIR among the ZCTAs with the lowest   
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SoVI® values of 0.15. There were 1,974 PrCA cases among veterans who lived in 
metropolitan ZCTA based of  
RUCA values with 362 deaths due to PrCA, for a MIR of 0.18. There were 1,098 PrCA 
cases among veterans who lived in non-metropolitan ZCTA based of RUCA values with 
172 deaths due to PrCA for a MIR of 0.16 (Figure 5.3). 
The global Moran’s I for PrCA MIRs by ZCTA was statistically non-significant (p-
value = 0.08). From this we can conclude that PrCA MIRs among SC veterans during the 
study timeframe among all SC ZCTAs did not exhibit spatial clustering. However, based 
on the local Moran’s I test, there are two statistically significant clusters of ZCTA (Figure 
5.4). 
5.5 Discussion 
The overall MIR for PrCA among veterans receiving care at VHA facilities from 
January 1, 1999 to December 31, 2015 of 0.17 is higher than the 2011 – 2015 national 
PrCA MIR of 0.15.38 
A distinct steep linear trend is observed in the MIR strata for the categories of 
age at first VA visit. Possible explanations for this trend include that veterans who start 
their VHA healthcare at younger ages are more likely to have preventive care visits. 
Another possibility is that veterans who wait to start their VHA care are doing so 
because of pre-existing conditions and are starting to go to VHA facilities to reduce the 
cost of healthcare from non-VHA sources. It needs to be noted that age of PrCA 
diagnosis was not used because there were several cases (not a majority) who did not 
have that information recorded in the VACCR.  
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As expected, those veterans who live in the ZCTAs deemed least vulnerable to 
the impact of natural disasters recovery efforts have lower MIRs than those who live in 
more vulnerable ZCTAs as well as the overall MIR. Interestingly, veterans living in ZCTAs 
that are deemed being at medium level of social vulnerbility have the highest MIRs 
among the three SoVI® strata. One possible explanation for this occurrence is that 
veterans who seek care at VHA facilities are less likely to reside in either the most or 
least affluent ZCTAs in SC; therefore, they are concentrated in ZCTAs that look more like 
the mean/median with respect to affluence. 
Veterans who are married also have a slightly lower PrCA MIR. It should be noted 
that married veterans comprise slightly less than 58% of the entire cohort. This confirms 
the established protective impact of marriage in PrCA survival.88 
There also was a rural/urban disparity observed in PrCA MIRs in this cohort. 
Veterans residing in metropolitan ZCTAs had a lower MIR than those observed for the 
overall cohort while veterans residing in non- metropolitan ZCTAs had higher a MIR than 
those observed for the overall cohort. This confirms that veterans in rural areas (like the 
general population) are at increased risk of not undergoing routine clinical care and 
therefore increased mortality for PrCA.8 
Interesting and counter to expectations, Blacks had a lower MIR than whites in 
this veteran population. Hebert et al. found that from 2001 to 2005 the statewide PrCA 
MIR for Blacks was 0.26 while for Whites it was 0.16.45 Comparing these MIR values 
raises many questions. Black veterans in SC comprise the majority of VHA PrCA patients 
in SC, which is not the situation among PrCA cases in the entire state of SC (where it is   
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closer to 40%) .39 One explanation for this observation is that whatever socio-economic 
latent factors influence the disparity in either the mortality, incidence, or both among 
Blacks in SC as compared to Whites are minimized by the care received at SC VHA 
facilities as compared to the rest of SC. Another, unique observation is that Whites have 
a higher PrCA MIR as compared to the general population in the state. Is the care 
provided for PrCA at SC VHA facilities better for Blacks but worse for Whites? This 
observation needs to be investigated further by determining MIRs for other cancers in 
veteran populations in SC and nationwide. 
It also was determined that clusters of higher than expected MIRs in ZCTAs exist 
in two portions of the Upstate Region of SC. What makes these areas at increased risk 
for high PrCA MIRs in the veteran population is unknown. However, the utility of 
applying a standard geospatial statistic to spatial MIR distributions resulted in this 
observation. This descriptive approach is the first step in determining the reasons for 
those clusters, and to test if those clusters persist in other cancers among veterans. 
In conclusion, the use of MIRs to describe PrCA epidemiology in South Carolina 
among veterans has served as an instrumental first step in understanding the 
epidemiology of PrCA in this population. This in turn has facilitated the development of 
several potential research hypotheses that will hopefully be evaluated. The first is to 
investigate why the PrCA MIR among SC Black veterans is lower than the statewide PrCA 
MIR for Blacks and/or conversely, why the PrCA MIR among SC White veterans is higher 
that the statewide PrCA MIR among SC Whites. The second is to evaluate in more detail 
the two statistically significant clusters isolated in one region of the state. How are the   
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MIR values with the clusters similar to each other and different from the surrounding 













































Figure 5.1. STROBE Diagram for the generation of the analytical cohort for survival 
modeling among the South Carolina veteran population with prostate cancer who seek 
healthcare at Veteran Health Administration facilities from January 1, 1999 to December 
31, 2015 and meet the study inclusion criteria 
 
964,047 unique patients in VA Cancer Registry 
775,769 unique patients in both VA Cancer Registry and VA MedSAS® Files 
235,782 prostate cancer patients 
539,987 non-prostate cancers patients 
230,401 prostate cancer patients not in South Carolina 
5,384 prostate cancer patients in South Carolina 
3,073 eligible prostate cancer patients in South Carolina 
917 prostate cancer diagnosis before 1/1/1999 
6 date of birth difference greater than 1 year between datasets 
1,178 age out of range
 103 not White or Black
 
3 missing date of prostate cancer diagnosis 
 






Figure 5.2. Overall and categorical mortality-to-incidence ratios among South 
Carolina veterans diagnosed with prostate cancer who receive care at US Veteran 
Health Administration facilities from January 1, 1999 to December 31, 2015 and meet 






Figure 5.3. Prostate cancer mortality-to-incidence ratios among South Carolina 
veterans who receive care at US Veteran Health Administration facilities by ZIP code 







Figure 5.4. Prostate cancer mortality-to-incidence ratios results of local Moran’s I 
among South Carolina veterans who receive care at US Veteran Health Administration 
facilities by ZIP code tabulation areas to identify MIR ZIP code tabulation area clusters 






6.1 Research Accomplishments 
Are there spatial variations that influence prostate cancer (PrCA) epidemiology 
among South Carolina (SC) veterans who receive their healthcare from the Veteran 
Health Administration (VHA)? This was the overarching hypothesis of this research 
project. Each aim of this research sought to evaluate the possibility of spatial variation in 
PrCA epidemiology in this cohort.  
Aim 1 (i.e. Chapter 3 of this dissertation) evaluated the influence of geospatial 
factors on the incidence of PrCA among SC veterans. The research undertaken for Aim 1 
determined that if a veteran resides 25 to 55 miles from his most frequently visited VA 
facility, he is approximately 20% more likely to develop PrCA when accounting for only 
individual-level factors and individual-level factors nested within ZIP code residence 
were the ZIP code is evaluated as random effect (Models 1 and 3 Table 3.3). However, 
distance traveled becomes a statistically non-significant predictor once ZIP code 
characteristics were evaluated; for these analyses, increasing social vulnerability using 
the Social Vulnerability Index (SoVI®) in the ZIP code increases the likelihood of 
developing PrCA by 27% and residing in a ZIP code with at least 15.86% percent of the 
population in poverty increases the risk of PrCA by 24% (Model 5 Table 3.3). 
Interestingly, the most appropriate model in predicting PrCA incidence within the 
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veteran population in South Carolina (SC) is the most complex model in which 
individual- and neighborhood -level factors, and the random effects and spatial 
autocorrelation of ZIP codes are accounted for (Model 7 Table 3.3). In this model, while 
distance traveled and percent of poverty in the ZIP code are statistically non-significant, 
increasing SoVI® in the ZIP remains statistically significant and increases the risk of PrCA 
by at least 35% (Model 7 Table 3.3). 
Based on these results we can conclude that no matter how complex the 
epidemiological model used for predicting PrCA, at least one geospatial factor predicts 
PrCA in veterans in SC, even after accounting for known individual-level factors. 
Furthermore, given how these factors vary between statistical significance and 
statistical non-significance, they may be accounting for a latent characteristic within the 
ZIP code that can be accounted for by several of these geospatial factors. These, in turn, 
may result in one geospatial factor remaining statistically significant while another 
geospatial factor becomes statistically insignificant. This phenomenon indicates possible 
research potential into expanding how to assess geospatial characteristics of ZIP codes 
to include environmental factors as well as evaluate if specific latent factors that 
comprise the SoVI® can serve as better predictors of PrCA incidence than the over 
SoVI®. It also highlights the fact that when we are able to move to larger geographical 
units, such as regions within the US or even the entire country, it is conceivable and  
indeed likely, that results that were statistically non-significant at a state level will 
emerge as significant in larger geographical units.  
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Aim 2 (i.e. Chapter 4 of this dissertation) evaluated the influence of geospatial 
factors on the mortality of PrCA among SC veterans. The research that was conducted 
for Aim 2 resulted in determining three things related to geospatial factors and PrCA 
mortality (Model 3 Table 4.3). The first is that a veteran traveling more than 55 miles 
was 26% more likely to die. The second is that the best-fitted model accounted for ZIP 
codes as random effects, which indicate the unique nature of ZIP code residence to this 
population regarding PrCA mortality. The third is that while it is best to account for the 
random effect of ZIP codes in this population; the ZIP code factors evaluated, however, 
were not appropriate in predicting PrCA mortality. Therefore, further research needs to 
be conducted to determine other geospatial factors that influence PrCA mortality in this 
population. 
Aim 3 (i.e. Chapter 5 of this dissertation) evaluated whether the mortality-to-
incidence ratio (MIR) of PrCA among SC veterans varied spatially across ZIP codes. While 
the overall distribution of PrCA MIRs across ZIP codes was found not to vary spatially; 
there were two distinct clusters of ZIP codes in the Upstate region of SC that had higher 
than expected PrCA MIRs as compared to their neighboring ZIP codes. 
Additionally, from a modeling perspective, this research was able to incorporate 
and evaluated simultaneously three distinct levels of spatial factors. This 
accomplishment is of central importance to Aims 1 and 2 (Chapters 4 and 5 of this 
dissertation). The first geospatial factor considered was the distance a SC veteran  
traveled from the ZIP code listed most often on in his VHA electronic medical records to 
the VHA facility that SC veteran traveled to most often. This geospatial factor was used   
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as a potential predictor at the individual-level unit of analyses. Second, we were able to: 
1) nest the veterans within each veteran’s ZIP code of residence and analyze that ZIP 
code as a random effect; and 2) evaluate ZIP code-level characteristics as possible 
predictors to consider at the second-level hierarchical unit of analyses. The third 
geospatial factor that was considered was the spatial autocorrelation between ZIP 
codes. The spatial autocorrelation was evaluated for the individual-level only predictors 
for PrCA and for both the individual- and nested-level factors for PrCA concurrently. 
Evaluation of the ZIP code spatial autocorrelation is important in 1) identifying ZIP codes 
with lower- and higher than expected occurrences of the outcome of interest (i.e. PrCA 
incidence in aim 1 and PrCA mortality in aim 2), and 2) it determines a risk estimates and 
corresponding 95% credible intervals for the geographical units of measurement (i.e. ZIP 
codes for this research). 
6.2 Research Strengths 
There are three core strengths of this dissertation research. The first is the 
dissemination of a novel analysis with value to epidemiologists, clinicians, and policy 
makers. Epidemiologists can use this approach to more thoroughly evaluate diseases. 
Clinicians can assess the work of epidemiologists to assess how much value to place on 
where their patients reside for specific disease. Policy makers can use this approach to 
assist in determining how best to allocate resources based on the risk for diseases on 
where individuals reside. As modelling approaches continue to evolve so, too, must the  
approach that epidemiologists use to identify and investigative health issues. This will 
facilitate our ability to evaluate the causes of disease and point to methods for   
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intervening to prevent and control PrCA. Understanding how to use and interpret the 
results of more advanced modeling equations that can account for nested and spatial 
variations will benefit the health delivery and scientific communities. 
Targeted research in specific, higher-than-normal-risk communities will allow 
researchers to investigate specific risk factors that are driving increased disease risk, 
especially risk of aggressive disease. In addition, this information will allow more 
community-specific interventions and prevention programs to be developed and 
evaluated. 
The second core strength is the use the use of a national cancer registry for an 
entire population; i.e., veterans who seek care in the VHA system. The VA Central 
Cancer Registry (VACCR) meets the highest cancer registry standards and is uniform in 
its data collection procedures for the entire US In addition, because this uses VHA data, 
conclusions from this dissertation may lead to further evaluations of the services 
received by veterans seeking care within the VHA system and/or improve the current 
services those veterans receive. 
The third core strength of this dissertation is that by utilizing a single state to 
establish the research approach, this approach can easily be applied to evaluate the 
epidemiology of PrCA incidence and mortality among veterans in larger geographical 
units, including on a national level. By better understanding the individual-level risk 
factors, neighborhood level risk factors, and spatial considerations associated with the 
incidence and mortality of PrCA; this will provide a template to evaluate other cancers   
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within the VHA population as well as provide a resource in shaping VHA policy 






My journey in obtaining my doctoral degree in epidemiology has been a long, 
interesting, challenging, and rewarding experience. Earning my doctorate is rewarding 
on my levels. It is obvious on an intellectual and academic level, demonstrating that one 
can undertake complex and thorough research, and understand the details of your field 
of study. 
For me, earning my doctorate has a unique personal quality. As a first-generation 
American, my parents passed up their academic and intellectual goals for the 
opportunity to immigrate to the United States. They sacrificed to earn a life in the 
United States so that their children may not have to make such difficult decisions in 
their lifetimes. They instilled in me and my siblings the importance of knowledge and 
wisdom that comes from intellectual endeavors. They reminded us that power and 
money are fleeting things that can be taken from anyone by force or lost by one’s follies. 
However, no one can take away one’s knowledge. 
My initial studies led to my first passion, biology. More specifically, the cell and 
how magnificently complex it is. I thought I would have a career as a bench scientist 
after I completed my undergraduate degree in biology. My first job after college was 
testing human samples for diseases using state-of-the-art techniques at Quest 
Diagnostics. I found the work rewarding. However, as I gained more experience and 
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learned more laboratory techniques; I found the work to border on mundane. There 
was no challenge in it for me.  
Serendipitously, Quest provided seminars for employees to better understand all 
aspects of the diseases we worked on. It was during these seminars that I found out 
about “epidemiology”. That was the first time that I heard of such a field. I found it 
fascinating that such a field requires so much cross-disciplinary skills and knowledge. I 
began to learn more about epidemiology with each seminar and my own study of it. I 
knew that I would eventually return to school to pursue a graduate degree. After more 
than two years of working for Quest, I decided to return to school; however, instead of 
cellular biology, I decided to pursue a Master’s in Public Health (MPH) degree.  
Of the school’s that accepted me, I chose Saint Louis University because it 
offered the degree with dual concentrations in epidemiology and biostatistics. I found 
the additional workload to meet the requirements for both concentrations fun. I 
enjoyed learning the core principals of epidemiology and the underlying statistics that 
enable epidemiologists to care out their work. 
One of the great features of the MPH program at Saint Louis University is that is 
requires 360 hours to be completed as an internship. I was fortunate to find my 
internship at the Infectious Disease Division at Washington University in Saint Louis. 
That internship turned into a job for me. I began by first assisting with research studies 
and then after a little over of year, I became a research coordinator for research studies. 
One of the great things about that job was the variety. I was part of case-control, 
retrospective cohort, prospective cohort, and randomized control trials. Each study was   
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unique. I was never bored. However, I learned the lesson that the freedom to conduct 
such a wide variety of studies in an academic environment comes with a price. More 
precisely, grant money. When grant funding runs out, so does your time for that type of 
research. 
Thankfully, my experience in epidemiological research led to me being hired by 
the St. Louis County Department of Health as an Epidemiologist. Specifically, I focused 
on bio-preparedness; bioterrorism, pandemics, unique outbreaks. Practically, while I 
needed to be well trained and knowledgeable in bio-preparedness, I was used as a 
general county epidemiology. Interestingly, the bio-preparedness that I was my primary 
focus was pandemic influenza. I was hired a year before the 2009 influenza season in 
which the major strain of the virus mutated more than was expected. Therefore that 
season’s influenza vaccine was mostly ineffective at the start of the influenza season 
while updated vaccines were being rushed into production for distribution. The 
pandemic influenza plan for St. Louis County that I had recently overhauled with major 
revisions was implemented. After the influenza season was over and based in part to my 
involvement in the response; the Director of Communicable Diseases strongly 
encouraged me to pursue my doctorate in epidemiology. He told me that he felt that I 
had the skill sets to one day sit in his position. I found the prospective of that potential 
future for myself rewarding, and so I applied to doctorate programs. 
Of the schools that accepted my application, I chose the University of South 
Carolina because of all the cross-disciplinary centers that the School of Public Health 
offered. Due to my experience as an epidemiologist, I was able to test out of all   
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introductory and mid-level epidemiology courses. This created a fortunate opportunity 
for me to befriend individuals who have been in the program for a year or two. Because 
of the resulting experiences, I was able to better navigate the course work requirements 
of the program and to learn about faculty whose classes I had not taken yet.  
One of those students at that time was Gowtham Rao who was nearly finished 
with his dissertation research at the VA. Sharing many of the interests in research, 
outlooks in conducting research, and personal characteristics; we became friends. It was 
Gowtham who introduced me to Dr. Charles Bennett in the College of Pharmacy and to 
Dr. Sue Haddock at the WJB Dorn Veteran’s Affairs (VA). It was Gowtham who showed 
me the research potential of using VA data, which he was using in his dissertation work. 
He was instrumental in opening up the VA to me to conduct research. 
After completing my coursework and passing my progression exam, I needed to 
develop a dissertation research project. I knew that I wanted to use VA data. What I did 
not know was the topic of my dissertation. As with many things, inspiration comes from 
many places. The first place was when I took Dr. Susan Steck’s Cancer Epidemiology 
course and my research project for the class was a literature review of prostate cancer 
temporal and spatial epidemiology. The second place was from concurrently taking my 
PhD Seminar course, which was being proctored by Dr. Swann Adams. She required the 
class to draft a mock NIH grant. I used the project for Dr. Steck’s course to serve as the 
Background Section of the mock grant for Dr. Adams’ course. Drawing inspiration from 
the literature search, I developed a potential study. I quickly realized that this mock 
grant can be used as a dissertation project. Next, I needed to find my committee.  
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Thankfully, I was not naive to the importance of choosing my dissertation 
committee and my dissertation research topic. This was in no small part to all my friends 
that I met when I started the program who were ahead of me in the dissertation 
process. I knew my committee could not and should not, should not and would not be a 
rubber stamp. I knew I needed to thoroughly assess my own characteristics to find 
individuals that would complement my strengths, improve my weaknesses, and provide 
examples to make me a better researcher, keep me focused, and critically assess my 
work. 
I knew that Dr. James Hébert would be ideal as my committee chairman. 
However, he was and is an extremely busy man. Would he have the time to serve on 
another dissertation committee? Would he have the interest in my dissertation project? 
Would he have the interest in me conducting that dissertation project? As it turned out, 
the answer to all those questions was “yes”. 
To Dr. James Hébert, 
Thank you for so much! It is because of you, more than most, that I am able to 
reach this pinnacle. You were the fire under my ass making sure I never rested. 
You were the beacon in the distance making sure I stayed focused. You shared my 
exasperation when the Cancer Registry was giving me the bureaucratic run 
around for almost a year. You shared my frustration when I spent almost a year 
trying to make aim 1 analysis work for larger cohorts and the nation. You shared  
my excitement with each new set of results. Your example epitomizes what it 
means to train the next generation of researchers so as to continuously carry   
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forward the need for better scientists to conduct better science. As wonderful as 
this experience has been for me, I’m looking just as forward to the next phase of 
my academic research career knowing that I have your guidance in helping me 
navigate what is unexplored territory for me. 
The next step after Dr. Hébert agreed to serve as my committee chairman was to 
find the other members. His first suggestion was Dr. Jan Eberth, who was at the time a 
new faculty member here. Dr. Hébert informed me that her research interests and 
experience overlaps with my proposed dissertation research. After meeting with Dr. 
Eberth and discussion my proposed dissertation research, she agreed to serve on my 
committee. 
To Dr. Jan Eberth, 
Thank you for taking a chance on me! We had never met prior to me asking you 
to serve on my committee. You will never know how much our meetings meant to 
me. You were a rock during this process. Constantly reminding me either 
implicitly or explicitly that “I am an Epidemiologist”, not a data manager. As 
someone who has a habit of getting mired in the details, having a constant such 
as yourself made it possible to know what specifically needed to get done and 
why. (the “why” sometimes took a little longer) 
The committee member that I absolutely knew that I would like to serve on my 
committee before I even began developing my dissertation proposal was Dr. Bo Cai. 
Having taken some courses from him, I knew that I could work well Dr. Cai.   
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To Dr. Bo Cai, 
Thank you for making sure I did not mess up my analyses. I know that I straddle 
the line between confidence and arrogance when it comes to my statistically 
ability. You made sure my dissertation research would not suffer from my 
arrogance. Without you, the results we found would have remained a mystery. 
You made sure you guided me to properly begin to learn and apply Bayesian 
statistics. You made sure the results were valid and that I understood those 
results. Because of you, we can replicate this analytical approach in future 
research projects. 
With the department faculty in place on my committee, I proceeded to select 
who would serve as outside members. Thankfully, the first choice made complete sense. 
Dr. Charles Bennett at the University of South Carolina College of Pharmacy is an 
oncologist at the VA who only cares for PrCA patients. In addition, he has extensive 
research experience with students and fellows doing PrCA research. Finally, I served as 
one of his graduate assistants during my academic studies. 
To Dr. Charles Bennett, 
It has been an amazing experience working for you. I have learned so such 
working on your studies that has expanded my knowledge in conducting 
epidemiological research. I have never met a scientist with as much passion in  
his/her area of expertise as you. You make research fun. It is only now, towards 
the end of my formal studies that understand why research can by fun. For that, 
I’ll forever be indebted to you.  
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I was must concerned about not being allowed to have my second outside 
committee member. Yet, it made logical sense to have him on my committee. Dr. 
Gowtham Rao, was a recent graduate with whom I had taken classes with. He was 
appointed as an adjunct faculty at the School of Public Health upon his graduation. His 
most important expertise as it related to my dissertation was that he was a beta-tester 
for analyzing VA electronic medical records in the VA’s, at the time, new virtual 
computing environment. In other words, he was part of a vanguard of VA health 
scientists in the nation using VA electronic medical records using 21st century 
technology. Thankfully for my dissertation research, the School of Public Health agreed 
with my reasons. 
To Dr. Gowtham Rao 
I’d like to believe that meeting you on my first day at the University of South 
Carolina was fated. You introduced me to a treasure trove of data that would 
take multiple lifetimes to address all possible research questions. You did not 
“hold my hand” but rather pointed me in the correct way and warned me if I was 
going down the wrong way. Because of the that, there are few epidemiologists in 
the nation who have had as much experience analyzing VA data using the 
benefits of the VA’s virtual environment. On behalf of my career, thank you for 
opening this world to me! 
Undertaken a dissertation research is like the journeys in literature’s greatest 
stories were the protagonist meets individuals that help him/her in his/her quest as 
he/she faces obstacles to overcome. Some are obvious; like family, friends, dissertation   
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committee members. Other’s are unexpected welcome additions. I had three such 
individuals. 
The first was Dr. Sue Haddock, who is the Associate Chief of Staff for Research at 
the WJB Dorn VA. Dr. Haddock has been instrumental in developing my career as a VA 
scientist while giving me latitude to finish my dissertation. 
To Dr. Sue Haddock, 
Thank you for making sure I didn’t lose myself in the government bureaucracy 
that can be overwhelming for new scientists working in the government. You 
made sure I didn’t burden myself with too many studies. You promoted my 
research and my expertise. Because of you, my research has begun to establish 
me as someone capable of conducting VA research. I am grateful to have met 
you; your genuine interest in both myself, my dissertation, and my other research 
has always been a welcoming encourage to keep progressing forward. 
The second was Dr. Linda Hazlett, who is the Graduate Director for Epidemiology 
at the School of Public Health. Students could ask for no better faculty advocate than Dr. 
Hazlett. 
To Dr. Linda Hazlett, 
Thank you for your sincere interest in my progress. Whenever I completed a 
milestone, whether major or minor in my dissertation progress, I knew that 
telling you in person would make it more “real”. Your positive encouragement 
was always appreciated and, at times, needed (even if it was unbeknownst to 
you). Even when you would tell me to “hurry it alone”, you did it with positive   
 
117 
reinforcement. You also made sure I didn’t forget some logistical issue that would 
prevent me from completing my dissertation. I don’t know how many student’s 
say this to you; “thank you”. 
The third person was by far the most unexpected, Dr. Christopher Emrich. Dr. 
Emrich was at the University of South Carolina College of Geography when I met him. I 
was interested in using the Social Vulnerability Index (SoVI®) that he oversees in my 
dissertation research. What resulted was a positive year of working and learning from 
him. Because of that experience, I was able to write a first draft grant proposal for a 
Public Health inspired SoVI® that I used as my comprehensive exam. 
To Dr. Chris Emrich, 
It may have been by happenstance that we met but working with you opened a 
new avenue for future research that I hope I get to do. I want to let you know 
that your assistance with my dissertation research improved how impactful the 
results are. My hope is that we both find the time to find the next project we can 
work on together instead of merely exchanging emails messages. 
In closing, this chapter was written for three reasons. The first to look back personally 
and take stock of what this experience has meant to me. The second to express how 
grateful I am to everyone that I mentioned directly and indirectly in the chapter. The 
third is in the hope that perhaps some doctoral student who is beginning his/her 
dissertation reads this and gleans some small amount of wisdom in how and what 
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